#1Company overview Financial review 2022 priorities Appendix References Q12022 Results Investor presentation U NOVARTIS | Reimagining Medicine#2Company overview Financial review 2022 priorities Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "potential," "expected," "will," "planned," "pipeline," "outlook," or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding potential future, pending or announced transactions, regarding potential future sales or earnings of the Group or any of its divisions; or by discussions of strategy, plans, expectations or intentions; or regarding the Group's liquidity or cash flow positions and its ability to meet its ongoing financial obligations and operational needs; or regarding the strategic review of Sandoz; or regarding our commitment to net zero emissions across our value chain by 2040; or regarding our new organizational structure. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: liquidity or cash flow disruptions affecting our ability to meet our ongoing financial obligations and to support our ongoing business activities; the potential that the strategic benefits, synergies or opportunities expected from our new organizational structure may not be realized or may be more difficult or take longer to realize than expected; the impact of a partial or complete failure of the return to normal global healthcare systems, including prescription dynamics; global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the products described in this presentation; the uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; safety, quality, data integrity, or manufacturing issues; uncertainties involved in the development or adoption of potentially transformational technologies and business models; uncertainties regarding actual or potential legal proceedings, investigations or disputes; our performance on environmental, social and governance measures; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. 2 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#3Company overview Financial review 2022 priorities Appendix References Vas Narasimhan Chief Executive Officer Company overview 3 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#4Company overview Financial review 2022 priorities Appendix References Novartis off to a solid start in Q1 across our value drivers Growth Group sales +5% cc IM sales +4% CC Sandoz sales +8% cc Productivity Group core operating income +9% cc IM core operating income +5% CC IM core margin 35.9% (+0.2%pts) cc Sandoz core operating income +26% cc 1 Innovation 3 PluvictoⓇ mCRPC post-taxane approved in US VijoiceⓇ PROS approved in US1 BeovuⓇ DME approved in EU KymriahⓇ r/r follicular lymphoma EU/EEA CHMP positive opinion JDQ443 encouraging early clinical data from Ph1b KontRASt-01 study¹ 2 ESG 4 AMR: extension / expansion of collaboration agreement with Ares Genetics, enabling genomic surveillance for resistant pathogens¹ Access: agreements signed in Zambia, Tanzania (e.g. SCD, HF, HTN) Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 35 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. IM - Innovative Medicines division. 1. Post quarter event. 4 Investor Relations | Q1 2022 Results ✓ NOVARTIS | Reimagining Medicine#5Company overview Financial review 2022 priorities Appendix References Q1 Innovative Medicines (IM) sales grew across US and ex-US, driven by our in-market growth drivers IM sales USD 10.2bn (+4% cc) US | Q1 2022 USD 3.7bn +3% cc Q1 2021 Q1 2022 1 GROWTH Growth drivers +21% cc, 56% of IM sales Ex-US | Q1 2022 USD 6.5bn +5% CC 7 Q1 2022 USD 5.7bn Q1 2021 Q1 2022 AimovigⓇ PiqrayⓇ 56% +21% vs. PY MayzentⓇ XiidraⓇ LutatheraⓇ 48% KymriahⓇ KesimptaⓇ KisqaliⓇ Q1 2021 Q1 2022 All % growth relate to cc unless otherwise stated 1. Includes XolairⓇ, BeovuⓇ, Adakveo®, TabrectaⓇ, ScemblixⓇ, Enerzair®, AtecturaⓇ, Leqvio ®, Luxturna and Pluvicto®. 5 Investor Relations | Q1 2022 Results llaris® ZolgensmaⓇ Jakavi® Tafinlar+MekinistⓇ PromactaⓇ EntrestoⓇ Cosentyx® Other¹ ✓ NOVARTIS | Reimagining Medicine#6Company overview Financial review 2022 priorities Appendix References Strong performance of EntrestoⓇ, KesimptaⓇ, Cosentyx®, ZolgensmaⓇ, Kisqali® and launching LeqvioⓇ... Q1 sales1 Entresto SCAND Kesimpta Sales USD million 1,093 195 Cosenty 1,159 106 zolgensma 363 44 KISQALI 239 44 nbocic Xolair 368 33 LARIS 285 29 PROMAGTA 491 28 ©JAKAVI 389 26 ruppened SCEMBLOX 25 25 MAYZENT 79 24 LEQVIO 14 13 Growth vs. PY USD million 145 Growth vs. PY CC 304 42% nm 12% 18% 28% 17% 18% 9% 14% nm 47% nm Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 35 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY nm not meaningful 1. Innovative Medicines division 6 Investor Relations | Q1 2022 Results 1 GROWTH ✓ NOVARTIS | Reimagining Medicine#7Company overview Financial review 2022 priorities Appendix References reinforcing our confidence in mid-term growth outlook Q1 sales Cosentyx USD 1.2 bn +12% 1 GROWTH CE Z KKǝL Entresto zolgensma KISQALI Kesimpta LEQVIO® USD 1.1 bn USD 0.4 bn USD 0.2 bn USD 0.2 bn nm +42% +18% +28% nm nm Est. CAGR (2020-26) Low double digit Peak sales USD >7bn US LOE 2029+ Est. CAGR (2020-26) Double digit until LoE Peak sales USD >5bn US LOE 2025-2036 Est. CAGR (2020-26) Low to mid teens Peak sales multi-bn¹ US LOE 2031+ Est. CAGR (2020-26) Low 30s² Peak sales multi-bn US LOE 2031+ Est. CAGR (2020-26) nm Peak sales multi-bn US LOE 2031+ Est. CAGR (2020-26) nm Peak sales multi-bn US LOE 2036+ nm not meaningful. All growth rates in constant currencies (cc). US LoEs are estimated based on relevant patents; further extensions possible. 1. Including ZolgensmaⓇ IT. 2. Including KisqaliⓇ adjuvant. 7 Investor Relations | Q1 2022 Results ✓ NOVARTIS | Reimagining Medicine#8Company overview Financial review 2022 priorities Appendix References CosentyxⓇ grew double digit Sales evolution USD m, % cc Ex-US US 1 GROWTH Cosentyx E AZ K KL +12% cc Maintaining strong momentum " Growing ahead of the market in rheumatology Steady volume growth in US / EU, acceleration in other international markets >700k patients across 5 indications treated worldwide since launch ☐ 1,159 1,053 500 408 ☐ China market expansion continues 645 659 Expecting double-digit growth in 2022 ◉ HS submissions in 2022 (~400k potential addressable patients) CHMP decision expected for JPSA / ERA in Q2 2022 Confirming expectations of USD 7bn+ peak sales Q1 2021 Q1 2022 HS - Hidradenitis Suppurativa JPSA - Juvenile Psoriatic Arthritis ERA - Enthesitis related arthritis 8 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#9Company overview Financial review 2022 priorities Appendix References Entresto® +42% cc, growing strongly across geographies Sales evolution USD m, % cc Ex-US US weekly NBRx1 New-to-brand prescriptions (000) US +42% cc 7 1,093 CO 6 8 789 551 5 407 4 542 3 Mm 382 2 Q1 2021 Q1 2022 01/19 04/19 07/19 10/19 01/20 04/20 07/20 10/20 01/21 04/21 NBRX New-to-brand Prescriptions 9 Investor Relations | Q1 2022 Results 07/21 10/21 01/22 04/22 ☐ 1 GROWTH C Entresto AZ K KL Strong quarter performance² ☐ US: growth across hospitals, cardiology and primary care ☐ Europe: strong demand growth China: NRDL-driven growth in HF/HTN Confident in future growth ☐ ☐ Broad evidence across clinical and real- world settings 3,4 Guidelines drive 1st choice in HFrEF5 Opportunity for further penetration in HF and uptake in HTN in China/ Japan² NRDL - National Reimbursement Drug List HF - Heart Failure HTN Hypertension See References at end of this presentation ✓ NOVARTIS | Reimagining Medicine#10Company overview Financial review 2022 priorities Appendix References ZolgensmaⓇ grew 18% cc with increasing access ex-US Sales evolution USD m, % cc Ex-US US 319 +18% cc 1 GROWTH C Ezolgensma K KL Q1 highlights Ex-US sales grew +32% cc, while US sales steady ☐ 363 " 250 200 119 113 Q1 2021 Q1 2022 1. With investigational OAV101 intrathecal administration 10 Investor Relations | Q1 2022 Results Over 2000 patients have been treated worldwide Future growth drivers ◉ Increase in newborn screening: currently at 95% in US, 25% in EU OAV101 IT data¹: STEER currently enrolling; STRENGTH to start in 2H22 New data at MDA 2022 reinforce Zolgensma IV clinical benefit Age-appropriate motor milestones in pre-symptomatic children with 3-copy SMN-2 backup gene (SPR1NT) Post-hoc analysis (START and STR1VE) of children with Type 1 SMA achieved / maintained important measures of bulbar function NOVARTIS | Reimagining Medicine#11Company overview Financial review 2022 priorities Appendix References 1 GROWTH KisqaliⓇ delivers double-digit growth across regions CEZ KISQALI K L Sales evolution USD m, % cc Ex-US US +28% cc 239 195 160 124 71 79 Q1 2021 Q1 2022 ■ CDK4/6 (TRX) market trending towards recovery to pre-COVID levels; US growth mainly driven by adjuvant use ■ KisqaliⓇ grew 28% cc vs. PY; US growing in line with market, Europe growing ahead of market ■ MONALEESA-2 results published in NEJM, showing ~5 years median overall survival, longest ever reported in aBC ■ NATALEE adjuvant study primary analysis now expected 2023 In ph3 randomized controlled trials, ribociclib + endocrine therapy has shown overall survival benefit in the first-line setting. 11 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#12Company overview Financial review 2022 priorities Appendix References Strong KesimptaⓇ launch in a suppressed market* US MS market* growth still suppressed NBRX 34k 30k 28k 27k. 23k' Q1/21 Q2/21 Q3/21 Q4/21 Q1/22 Sales evolution 1 GROWTH CE Z K Kesimpta L Accelerating launch momentum " About 20k patients treated, >60% naive or first switch4 US: strong growth despite suppressed market dynamics Ex-US: approved in 68 countries Strengthening differentiation and benefit/ risk profile " Up to 4 years data show continued reduced risk of disability worsening and stable IgG levels (ASCLEPIOS/ALITHIOS)1,2 Majority of Kesimpta treated patients can mount a robust immune response after COVID-19 vaccination; may be distinct amongst B cell treatments³ USD m Ex-US US 195 ■ 147 109 66 50 Q1/21 Q2/21 Q3/21 Q4/21 Q1/22 *Refers to dynamic market. NBRX - New to brand Prescription IgG - Immunoglobulin G mRNA-messenger Ribonucleic Acid. See References at end of this presentation. 12 Investor Relations | Q1 2022 Results ✓ NOVARTIS | Reimagining Medicine#13Company overview Financial review 2022 priorities Appendix References 1 GROWTH Leqvio® US launch in line with expectations Driving broad customer engagement of prioritized HCPs reached¹ increase in unaided awareness² CE Z KK LEQVIO Establishing access and acquisition pathways >35 of ~200 prioritized systems have ordered Leqvio³ of corporate AIC accounts have purchased Leqvio³ >90% >2x ~55% 2 doses* a year seen as key differentiator2 >30% of customers have placed repeat orders³ DTC initiated -50% lives have coverage aligned to label4 Permanent J-code (J1306) has been granted and will go into effect July 1, providing greater reimbursement confidence HCP Healthcare Professional AIC - Alternative Injection Center 1. Internal tracking. Data on file 2. Compared to Q4 2021. Based on market research. Data on file 3. Based on sales data, Data on file. 4. Internal tracking of Formal medical policies published to date and early reimbursement experience. Data on file. *LEQVIO® is administered initially, again at 3 months, and then once every 6 months. 13 Investor Relations | Q1 2022 Results ✓ NOVARTIS | Reimagining Medicine#14Company overview Financial review 2022 priorities Appendix References 1 GROWTH ScemblixⓇ US launch off to a strong start NBRx share (rolling 3 months) CE AZ K KL SCEMBLIX® Strong launch execution Uptake driven by patients with resistance/intolerance to other TKIs Oct 21 Sprycel Tasigna Imatinib Gleevec Bosulif Iclusig Scemblix $25m 20% NBRX share in CML (across lines) 20% 19% 49% 3L+ patient share 12% 85% FF calls F2F, supporting strong SOV 5% 1L Ph3 study enrolling ahead of plan Nov 21 Dec 21 Jan 22 Feb 22 FF Field force SOV Share of voice 14 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#15Company overview Financial review 2022 priorities Appendix References 1 GROWTH Positive leading indicators for Pluvicto™ US launch Strong benefit/risk profile reflected in label Population: PSMA+ mCRPC patients post ARPI and taxane1 Patient selection: Using LocametzⓇ or other approved 68Ga-PSMA-11 agent¹ Clinical benefit: 38% reduction in risk of death vs. SOC alone¹ Administration: Up to 6 infusions, 6 weeks apart¹ CE PZ K KL PLUVICTO US launch building on LutatheraⓇ experience Commercial field teams trained on promotional materials <5 days High awareness among ~240 target RLT treatment centers (existing LutatheraⓇ sites) 96% of RLT centers have product purchase agreements in place >40 RLT centers onboarded to ordering system; first patients infused in April ☑ CMS applications submitted for permanent A code, expected to be effective in October EU approval anticipated in H2 2022. Additional Ph3 studies ongoing in pre-taxane and hormone sensitive settings, with potential to expand patient population for Pluvicto™ 3-4x. Evaluating additional Ph3 studies. 1. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2022. 15 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#16Company overview Financial review 2022 priorities Appendix References Sandoz business dynamics continue to normalize, benefitting from a lower prior year comparison SANDOZ Sandoz stabilizing Q1 sales USD 2.4 bn (+8%) driven by Europe (+9%) ■ Retail USD 1.8 bn (+11%) ■ Biopharma USD 0.5 bn (+7%) ◉ Benefitting from low PY comparator Core Operating Income USD 538m (+26%) Benefitting from low PY comp (due to cough & cold season) Assumptions for FY Continuing geopolitical uncertainty, price erosion, inflationary pressures Solid base for strong mid-term growth Driven by biosimilars, significant LOE opportunity Targeting USD 80bn originator sales (2030) Critical success factors on track Leading biosimilars pipeline: 15+ assets Manufacturing scale and expertise ✓ Development and regulatory experience Global footprint Experience in commercialization Leading in Europe; expanding US, ROW Strategic review of Sandoz continues to progress, update expected at latest by end 2022 All % growth relate to cc unless otherwise stated 16 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#17Company overview Financial review 2022 priorities Appendix References Broad pipeline of novel medicines continued to progress in Q1 Approvals PluvictoⓇ Vijoice®1 US: mCRPC post-taxane US: PROS 3 INNOVATION Neuroscience Cardio-Renal Oncology Immunology Readouts and publications Tislelizumab JDQ443 Ph3 Gastric cancer (primary OS endpoint) Encouraging early data (Ph1b KontRASt-01) ScemblixⓇ BeovuⓇ JP: CML 3L EU: DME Tafinlar+Mekinist CN: NSCLC with BRAF V600 mutation Submissions Designations Iptacopan Tislelizumab ScemblixⓇ Tislelizumab AimovigⓇ EU: NSCLC, 2L ESCC CN: Migraine 1. Post quarter event Selected milestones 17 Investor Relations | Q1 2022 Results China Breakthrough in C3G US Orphan in 1L nasopharyngeal cancer JP priority review in CML 3L Major study starts T-Charge T PHE885 Ph2 in Multiple Myeloma ZolgensmaⓇ Ph3 SMA IT (STEER) ✓ NOVARTIS | Reimagining Medicine#18Best percentage change from baseline (%) Company overview Financial review 2022 priorities Appendix References JDQ443 showed early sign of clinical activity with acceptable safety and tolerability 3 INNOVATION KontRASt-01: Phase 1b/2 study of JDQ443 in advanced, KRAS G12C-mutated solid tumors Best ORR across all doses in NSCLC JDQ443, a novel KRAS G12Ci, demonstrated a competitive safety and efficacy profile in NSCLC 100- 50- 20- 30- $ 60- Starting de 200 ng QO 400 mg QO 200mg BD Dose increase to 200 mg BID ■ ORR of 57% (4/7) at the RD of 200 mg BID ■ ORR of 45% (9/20) across all dose levels ■ No Grade 3 or higher treatment-related AEs at RD JDQ443 achieved high systemic exposure PK/PD modelling predicted sustained, high-level target occupancy at the RD Further development ongoing ☐ KontRASt-01 actively recruiting into SHP2i (TNO155) and anti-PD1 (tislelizumab) combo cohorts ◉ KontRASt-02 Ph3 JDQ443 monotherapy vs docetaxel in NSCLC opening soon Data presented at American Association for Cancer Research ORR Objective response rate RD - Recommended dose BID Orally twice daily 18 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#19Company overview Financial review 2022 priorities Appendix References 3 INNOVATION NATALEE: Latest event rate forecast indicates readout now in 2023, as event rate lower than originally projected CEZ KISQALI K L NATALEE study design HR+/HER2- eBC RIB+ ET R Pre- and post- menopausal 1:1 Anatomic Stage II & III N=5000 ET Ribociclib 400mg/day 3 weeks on/1 week off 36 months (~39 cycles) 36 months 60 months NSAI 60 months [+goserelin in pre-menopausal women & men] NSAI 60 months 60 months [+ goserelin in pre-menopausal women & men] eBC - early breast cancer 1. Projections based on data up to 03-Mar-2022. As of 20-Apr-2022, 303 events have been documented. 19 Investor Relations | Q1 2022 Results ☐ ☐ Recruitment completed to 5,000 patients, including intermediate and high risk (Apr 2021) Primary analysis planned at 500 iDFS events; ~300 events to date Successfully completed futility analysis in Q1 2022 Two interim analyses for efficacy planned; none has occurred yet ■ Discontinuation rate remains low NOVARTIS | Reimagining Medicine#20Company overview Financial review 2022 priorities Appendix References 2022 events¹ (expected) 3 INNOVATION ✓ Achieved NME Lead Regulatory H1 Pluvicto™ mCRPC (US/EU) decisions H1 VijoiceⓇ PROS (US) H2 ScemblixⓇ 3L CML (JP/EU) H2 tislelizumab ESCC 2L (US) Readout not supportive × Missed Other readouts H1 sabatolimab HR-MDS Ph2 H1 CosentyxⓇ Lichen planus Ph2 PRELUDE H1 CosentyxⓇ axSpA IV Ph3 INVIGORATE-1 H1 icenticaftor COPD Ph2b Submissions H1 H2 H1/H2 JakaviⓇ acute & chronic GVHD (EU /JP) H1/H2 KymriahⓇ r/r follicular lymphoma (US/EU/JP) H1/H2 BeovuⓇ DME (US/EU ✓/JP) ensovibep COVID-19 (US ✓) H1/H2 Cosentyx® HS (EU/US) H1/H2 tislelizumab NSCLC (EU/US) tislelizumab 1L Nasopharyngeal cancer (US) H2 UNR844 presbyopia Ph2 READER Ph3/pivotal study starts H1 CosentyxⓇ peripheral SpA H1 OAV101 SMA IT STEER ✔ H1 ensovibep COVID-19 (EMPATHY Part B) H2 JDQ443 NSCLC mono H2 ianalumab Sjögren's Syndrome H2 ianalumab Lupus Nephritis H2 CosentyxⓇ Psoriatic Arthritis IV (US) H2 ociperlimab solid tumors Submissions- H2 canakinumab NSCLC Ph3 Canopy A H2 TM Pluvicto nmCRPC enabling H2 iptacopan PNH Ph3 APPLY-PNH H2 YTB323 2L DLBCL readouts H2 KisqaliⓇ HR+/HER2- BC (adj) Ph3 NATALEE (event driven now moving to 2023) H2 OAV101 SMA IT Ph3b STRENGTH H2 lutetium (177Lu) vipivotide tetraxetan mCRPC1, pre-taxane Ph3 PSMAfore² 1. Selected. 2. Could move to early 2023. 20 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#21Company overview Financial review 2022 priorities Appendix References Harry Kirsch Chief Financial Officer Financial review and 2022 guidance 21 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#22Company overview Financial review 2022 priorities Appendix References Q1 mid single-digit sales and high single-digit Core Oplnc growth Change vs. PY Group1 USD million Net sales Core operating income Operating income Net income Q1 2022 % USD %CC 12,531 1 4,083 3 2,852 18 2,219 8 15 Growth ex. prior year Roche income 23 32 Core EPS (USD) 1.46 -4 Growth ex. prior year Roche income 6 EPS (USD) 1.00 10 17 Growth ex. prior year Roche income 25 56652 2272 9 12 34 Free cash flow 920 -42 Growth ex. prior year Roche dividend -14 1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 35 of the Condensed Interim Financial Report. A reconciliation of 2021 IFRS results and non- IFRS measures core results and free cash flow to exclude the impacts of the 2021 divestment of our Roche investment can be found on page 40 of the Condensed Interim Financial Report. The free cash flow impact represents the dividend received in Q1 2021 from Roche in relation to the distribution of its 2020 net income. 22 Investor Relations | Q1 2022 Results ✓ NOVARTIS | Reimagining Medicine#23Company overview Financial review 2022 priorities Appendix References Q1 Group core margin increased by 110bps to 32.6% driven by Sandoz which benefitted from low PY base Q1 2022 Net sales change vs PY1 Core operating income change vs. PY1 Core margin¹ % CC % CC % Core margin change vs. PY1 %pts cc Innovative Medicines 4 5 35.9 0.2 Sandoz 8 26 22.8 3.3 Group 5 9 32.6 1.1 1. Constant currencies (cc), core results are non-IFRS measures. An explanation of non-IFRS measures can be found on page 35 of the Condensed Interim Financial Report. 23 Investor Relations | Q1 2022 Results ✓ NOVARTIS | Reimagining Medicine#24Company overview Financial review 2022 priorities Appendix References 2022 Novartis full year guidance Barring unforeseen events; growth vs. PY in cc Innovative Medicines Sales expected to grow mid single digit Core Oplnc expected to grow mid to high single digit, ahead of sales Sandoz Sales expected to be broadly in line with prior year Core Oplnc expected to decline low to mid single digit Sales expected to grow mid single digit Group Core Oplnc expected to grow mid single digit Key assumptions Our guidance assumes that we see a continuing return to normal global healthcare systems, including prescription dynamics, and that no SandostatinⓇ LAR generics enter in the US 24 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#25Company overview Financial review 2022 priorities Appendix References Expected currency impact for full year 2022 Currency impact vs. PY %pts, assuming late-April exchange rates prevail in 2022 2 FX impact on Net sales FY 2021 I FX impact on Core operating income I 2 T -4 -4 I -5 to -6 I -6 -6 -5 I Q1 Q2 FY FY Q1 Q2 FY I I 2022 2021 2022 Actual Simulation 25 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#26Company overview Financial review 2022 priorities Appendix References Vas Narasimhan Chief Executive Officer 26 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#27Company overview Financial review 2022 priorities Appendix References Novartis appoints Aharon (Ronny) Gal, Ph.D. as Chief Strategy & Growth Officer 27 Investor Relations | Q1 2022 Results Effective no later than August 1, 2022 Leads the newly created Strategy & Growth function that combines corporate strategy, R&D portfolio strategy and business development ■ Reports to CEO and joins Executive Committee of Novartis ■ Brings over 20 years of life-sciences industry experience including financial research and analytics, management consulting and business development NOVARTIS | Reimagining Medicine#28Company overview Financial review 2022 priorities Appendix References Top 2022 priorities for Novartis on track 1 Successful launches: Leqvio®, KesimptaⓇ, Pluvicto™, ScemblixⓇ 2 Maintain growth momentum: C E AZ KK L 3 Progress pipeline: 20+ assets with significant sales potential, approval by 2026, on track 4 Optimize portfolio: Sandoz review, update end 2022; disciplined business development 5 Deliver returns: Continue productivity initiatives. New organizational model announced 6 Reinforce foundations: Culture to drive performance, data science to drive value, ESG leadership 28 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#29Company overview Financial performance Financial review Appendix 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials References Abbreviations 29 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#30Company overview Financial performance Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials References Abbreviations Net debt increased by USD 9.8bn mainly due to the annual dividend payment and share buybacks (USD bn) -0.9 -7.5 -0.8 -9.8 -10.7 Dec 31, 2021 Dividends M&A transactions -2.4 Treasury share transactions, net 0.9 Free Cash Flow Mar 31, 2022 30 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#31Company overview Financial performance Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials References Abbreviations Q1 2022 free cash flow decreased to USD 0.9bn mainly due to the loss of the Roche dividend in the prior year quarter Group free cash flow¹ USD bn, % USD 1.6 -42% Key drivers vs. PY - - 0.9 + Lower dividends from associated companies (PY Roche cash inflow of USD 0.5bn) Unfavorable working capital Favorable hedging results Q1 2021 Q1 2022 Excluding PY Roche annual dividend, free cash flow declined -14% (USD) 1. Free cash flow is a non-IFRS measure. An explanation of non-IFRS measures can be found on page 35 of the Condensed Interim Financial Report. 31 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#32Company overview Financial performance Financial review 2022 priorities Appendix Innovation: Clinical trials Innovation: Pipeline overview References Abbreviations Novartis is committed to driving consistent growth through 2030 and beyond IM sales evolution Illustrative, USD bn, % CAGR CC +8%¹ 38 39 35 49 >Median (aspiration) ≥4% 42 2 3 2026 2030 >2030 1 2020-2026 |≥4% Focused resources on key growth brands and launches, upscaling next generation engagement models 2 2026-2030 | >peer median Double-down on internal pipeline assets to unlock their full potential and add complementary BD&L 3 >2030 |>peer median Focused investments in technology platforms while staying at the forefront of innovation in small and large molecules нн 2018 2019 2020 2021 1.6% in USD. 32 Investor Relations | Q1 2022 Results U NOVARTIS | Reimagining Medicine#33Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Appendix Innovation: Clinical trials References Abbreviations Confident in future growth driven by our strength and depth in cardio-renal, immunology, neuroscience... Selected assets, nearly all with exclusivity into 2030+ New for Q1 Cardio-Renal Immunology Asset Indication Peak Sales Next Milestone/ Status Submission Asset Indication Peak Sales Next Milestone/ Status Submission Leqvio® CVRR-LDLC Ph3 ORION-4 and VICTORION-2- 2026+ PREVENT ongoing CosentyxⓇ HS Ph3 SUNRISE, SUNSHINE positive readout 2022 Primary prevention initiation Iptacopan1 IgAN Ph3 APPLAUSE-IgAN ongoing 20232 C3G iMN Pelacarsen CVRR-Lp(a) Ph3 APPEAR-C3G ongoing 2023 GCA Lupus Nephritis Lichen Planus Ph3 ongoing 2024 Ph3 SELUNE ongoing 2026+ Ph2b PRELUDE readout in 2022 2025 Ph2b ongoing Ph3 Lp(a)HORIZON ongoing 2026+ 2025 Ligelizumab Remibrutinib1 Food allergy³ Ph3 ongoing 2025 CSU Ph3 REMIX-1 and -2 ongoing 2024 Neuroscience Asset Indication Peak Sales Next Milestone/ Status Submission lanalumab Other indications being explored Sjögren's SLE Ph3 start in 2022 2026+ Ph2a ongoing 2026+ ZolgensmaⓇ SMA IT Ph3 STEER initiated 2025 Autoimmune hepatitis Ph2b ongoing 2026+ Branaplam Huntington's disease Ph2b VIBRANT-HD ongoing 2026+ Lupus Nephritis Ph3 start in 2022 2026+ Iscalimab Sjögren's Ph2b ongoing 2026+ Remibrutinib¹ Multiple sclerosis Ph3 REMODEL-1 and -2 ongoing 2025 Liver Tx Ph2b ongoing 2026+ DLX313 (UCB0599) Parkinson's disease Ph2 ongoing 2026+ HS Ph2a ongoing 2026+ Unprobabilized peak sales (USD): ⚫ <1bn •⚫ 1-2bn ... >2bn 'Wild Cards' LNA043 (osteoarthritis: Ph2 ongoing), ecleralimab (CSJ117 asthma: Ph2b ongoing, COPD: Ph2 ongoing), QBW251 (COPD: Ph2b readout imminent), SAF312 (COSP: Ph2b ongoing), UNR844 (presbyopia: Ph2b readout H2 2022) 1. Peak sales potential based on all studied indications. 2. Based on 9 months UPCR readout (US accelerated approval). 3. Food Allergy indication falls within the Respiratory & Allergy therapeutic area. 33 Investor Relations | Q1 2022 Results U NOVARTIS | Reimagining Medicine#34Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview and strength and depth in oncology Appendix Innovation: Clinical trials References Abbreviations Selected assets, nearly all with exclusivity into 2030+ Solid Tumors New for Q1 Hematology Asset Indication Peak Sales Next Milestone/ Status Submission Asset Indication Peak Sales Next Milestone/ Status Submission Kisqali® HR+/HER2- BC (adj) Ph3 NATALEE readout event- 2023 driven, expected 2023 Canakinumab NSCLC adjuvant Ph3 CANOPY-A readout in 2022 2023 ScemblixⓇ (asciminib) Iptacopan² CML 3L CML 1L PNH US and JP approved Ph3 ongoing 2025 Readout in 2022 (APPLY-PNH - 2023 enrollment completed) PluvictoⓇ mCRPC post-taxane US approved aHUS Ph3 ongoing 2025 mCRPC pre-taxane Ph3 PSMAfore readout event-driven, end 20221 2023 Sabatolimab HR-MDS Ph2 STIMULUS-MDS-1 2022/2023 continues to PFS readout³ MHSPC Ph3 PSMAddition ongoing 2024 JDQ443 2/3L NSCLC (mono) Tislelizumab² KRAS inhibitor TNO155 SHP2 inhibitor NSCLC (combo) Solid tumors: multiple combinations being explored in ongoing trials 2L esophageal cancer NSCLC Ph3 start in H2 2022 Ph2 ongoing 2024 AML 2026+ YTB323 CD19 CAR-T Non-Hodgkin's Lymphoma Ph3 STIMULUS-MDS-2 ongoing Ph2 STIMULUS-AML-1 ongoing Ph3 start 2022 2024 2025 Submitted in EU PHE885 BCMA CART-T Submitted in EU H2 2022 2L US submission Multiple myeloma Unprobabilized peak sales (USD): ⚫ <1bn Ph2 initiated 2024 .. 1-2bn ... >2bn Other indications Ociperlimab² NSCLC TIGIT mab Other indications Ongoing trials Ph3 ongoing4 Ongoing trials4; additional Ph3 study initiation H2 2022 'Wild Cards' | 1. Could move to early 2023. NIS793 (1L MPDAC: Ph3 ongoing, 1L metastatic colorectal cancer: Ph2 ongoing) 2. Peak sales potential based on all studied indications; Novartis territories. 3. Planned DMC readout for CR completed, study continues blinded to PFS readout, with submission in 2022/2023 using PFS and/or OS outcomes of Ph2 and/or Ph3 trial. 4. Active trials are being conducted by BeiGene, option deal. 34 Investor Relations | Q1 2022 Results U NOVARTIS | Reimagining Medicine#35Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Appendix Innovation: Clinical trials References Abbreviations 20+ potential billion USD+ pipeline assets with approval by 2026 Most are supported by high strength of evidence Selected assets Unprobabilized peak sales USD bn / multi-bn Strength of evidence Moderate Sabatolimab MDS; AML NIS793 PDAC; Colorectal Cancer Pelacarsen CVRR Canakinumab Adj. NSCLC Ociperlimab¹ NSCLC UNR844 Presbyopia Libvatrep (SAF312) Chronic Ocular Surface Pain TNO155, JDQ443² NSCLC; Colorectal Cancer; Combos Iptacopan PNH; C3G; IgAN; aHUS Remibrutinib CSU; MS Zolgensma SMA IT Ligelizumab FA Ociperlimab NSCLC Strength of evidence High Kisqali Adj. BC (+endocrine th.) YTB323² 2L DLBCL lanalumab Sjogren's; SLE; AIH; Lupus Nephritis Ensovibep Coronavirus infection Leqvio Hypercholesterolemia Cosentyx Multiple indications Pluvicto ✓ mCRPC post-taxane; mCRPC pre-taxane; mHSPC Scemblix ✓ 3L+ CML; 1L CML Tislelizumab Multiple indications Piqray (alpelisib) ✓ PROS; HER2+ adv BC; TNBC; ovarian cancer Most advanced and key indication(s) approved by 2026 Submission Phase III Phase II LCM ✓ Approved Unprobabilized peak sales up to USD 1bn Lutathera 1L G2/G3 NET Kymriah r/r Follicular Lymphoma Tafinlar/Mekinist Solid Tumor Agnostic Beovu DME Jakavi SR GvHD Strength of evidence based on the most advanced indication: High if in Ph3 or when Ph2 results available for the same MoA in the lead indication. 1. BeiGene option deal. 2. Ph3 to start in 2022. Assets are shown in the phase of the most advanced indication (listed first). Value based on the total of the listed indication(s). 35 Investor Relations | Q1 2022 Results U NOVARTIS | Reimagining Medicine#36Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Appendix Innovation: Clinical trials References Abbreviations Key milestones of pipeline assets with significant sales potential with approval by 2026 Selected assets, most advanced and key indication(s) approved by 2026 High strength of evidence Iptacopan PNH Iptacopan C3G Iptacopan aHUS Iptacopan IgAn Remibrutinib CSU 2022 Ph3 readout 2023 Submission 2024 2025 2026 High strength of evidence Ensovibep Coronavirus infection 2022 Submission 2023 2024 2025 2026 Ph3 read/sub Scemblix Approval Scemblix CML 1L Ph3 readout Submission Ph3 readout Submission Vijoice PROS Approval Ph3 read/sub Piqray Ovarian Cancer Ph3 read/sub Ph3 read/sub Piqray TNBC Ph3 read/sub Ph3 read/sub Piqray HER2+ adv BC Ph3 read/sub Ph3 readout Submission Tislelizumab Submissions and approvals of several indications Ph3 read/sub Remibrutinib MS Zolgensma SMA IT Ligelizumab Food Allergy Kisqali Ph3 read/sub YTB323 2L DLBCL Ph3 start lanalumab Sjögren's Ph3 start lanalumab LN Ph3 start Cosentyx HS Cosentyx Lichen Planus Cosentyx GCA Pluvicto mCRPCR post taxane Pluvicto mCRPCR pre taxane Pluvicto tetraxetan mHSPC NME Lead 1. Event driven, could move to early 2023. 36 Investor Relations | Q1 2022 Results Moderate strength of evidence Ph3 read/sub Sabatolimab MDS 2022 Ph2 readout 2023 2024 2025 2026 Ph3 read/sub Sabatolimab AML Ph3 readout Ph3 readout Submission in 2022/23 Submission Ph3 read/sub NIS793 PDAC Ph3 read/sub Submission Ph2 readout Pelacarsen CVRR Ph3 read/sub Submission Ph3 read/sub Canakinumab Adj. NSCLC Ph3 readout Submission Ociperlimab Approved UNR844 Presbyopia Ph3 start Ph2 readout BeiGene option deal Submission Ph3 readout¹ Submission Ph3 read/sub Libvatrep COSP Ph2 readout Submission JDQ443 NSCLC JDQ443+TNO155 NSCLC Ph3 start Submission Ph3 start Submission ✓ NOVARTIS | Reimagining Medicine#37Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Our pipeline projects at a glance Innovative medicines Solid Tumors Hematology Immunology Neuroscience Cardiovascular, Renal, Metabolism Others Ophthalmology Respiratory & Allergy Global Health Biosimilars 37 Investor Relations | Q1 2022 Results Appendix Innovation: Clinical trials References Abbreviations Phase 1/2 104 Phase 3 Registration Total 50 6 160 25 20 2 47 20 LO 22652 7 3 30 7 0 33 5 0 11 6 0 11 5 1 28 6 1 0 7 8 3 0 11 8 1 1 10 0 2 2 2 Total 104 52 6 162 NOVARTIS | Reimagining Medicine#38Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis pipeline in Phase 1 Appendix Innovation: Clinical trials AAA603 AAA817 Solid tumors Code Name 177Lu-NeoB Ac-PSMA-617 ADPT01 ADPT01 DFF332 DFF332 DKY709 IAG933 IAG933 JDQ443 JDQ443 KAZ954 KAZ954 Solid tumors NIS793 NIS793, spartalizumab TGFB1 inhibitor Solid tumors NIZ985 NIZ985, spartalizumab IL-15 agonist Solid tumors NZV930 NZV930, spartalizumab, NIR178 CD73 antagonist Solid tumors PDR001 spartalizumab PD1 inhibitor Solid tumors (combo) TNO155 TNO155 SHP2 inhibitor Solid tumors (combo) VPM087 gevokizumab WNT974 WNT974 spartalizumab IL-1 beta antagonist Porcupine inhibitor Colorectal cancer, 1st line Solid tumors Hematology Mechanism Indication(s) Code Name Radioligand therapy target GRPR Radioligand therapy target PSMA Multiple solid tumors ADPT03 ADPT03 KRAS Inhibitor DKY709spartalizumab HIF2A inhibitor Novel immunomodulatory agent Mesothelioma KRAS G12C mutated solid tumors Metastatic castration-resistant prostate cancer Colorectal cancer (combos) Renal cell carcinoma Cancers HDM201 HDM201 + MBG453, venetoclax JBH492 JBH492 JEZ567 JEZ567 MAK683 MAK683 MBG453 sabatolimab MIK665 MIK665 VAY736 ianalumab + ibrutinib VOB560 VOB560 WVT078 WVT078 YTB323 YTB323 Immunology Code Name FIA586 FIA586 MHS552 MHS552 MHV370 MHV370 NGI226 NG1226 Neuroscience Code NIO752 Others Code Name Global Health Mechanism Indication(s) Non-alcoholic steatohepatitis (NASH) EYU688 Autoimmune indications KAF156 EYU688 ganaplacide Systemic lupus erythematosus Tendinopathy INE963 INE963 Respiratory & Allergy Name NIO752 Mechanism Indication(s) Tau antagonist Progressive supranuclear palsy 38 Investor Relations | Q1 2022 Results LTP001 LTP001 NCJ424 NCJ424 Ophtalmology MHU650 MHU650 References Abbreviations 28 lead indications Lead indication Mechanism BCL11A MDM2 inhibitor CD123 CAR-T EED inhibitor TIM3 antagonist MCL1 inhibitor BAFF-R inhibitor CD19 CAR-T Indication(s) Sickle cell anemia Haematological malignancy Haematological malignancy Acute myeloid leukaemia Cancers Low risk myelodysplastic syndrome Acute myeloid leukaemia (combo) Haematological malignancy Cancers Multiple myeloma DLBCL and adult ALL Mechanism NS4B inhibitor Indication(s) Dengue Malaria prophylaxis Malaria, uncomplicated Respiratory diseases Respiratory diseases Diabetic eye diseases NOVARTIS | Reimagining Medicine#39Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis pipeline in Phase 2 Solid Tumors Code Name AAA601 LutatheraⓇ Mechanism Indication(s) Radioligand therapy target SSTR GEPNET, pediatrics 1L ES-SCLC Glioblastoma BLZ945 sotuletinib DRB436 Tafinlare + Mekinist® TabrectaⓇ CSF-1R inhibitor BRAF inhibitor + MEK inhibitor Met inhibitor KRAS inhibitor INC280 JDQ443 JDQ443 NIR178 NIS793 NIR178, spartalizumab NIS793 Ad2AR inhibitor, PD1 inhibitor TNO155 TNO155 TGFB1 inhibitor SHP2 inhibitor Solid tumors HGG/LGG, pediatrics Non-small cell lung cancer (Combo) NSCLC (combo) Cancers 1L metastatic colorectal cancer Solid tumors (single agent) Immunology Hidradenitis suppurativa Code Name Mechanism AIN457 Cosentyx® IL17A inhibitor Indication(s) Lichen planus CFZ533 iscalimab CD40 inhibitor Sjögren's Liver Tx CMK389 CMK389 DFV890 DFV890 IL-18 inhibitor Atopic dermatitis NLRP3 inhibitor Osteoarthritis LJN452 tropifexor + licogliflozin LNA043 LNA043 LOU064 remibrutinib FXR agonist Familial cold auto-inflammatory syndrome Non-alcoholic steatohepatitis (Combos) ANGPTL3 agonist Knee osteoarthritis BTK inhibitor Sjögren's LRX712 LRX712 LYS006 LYS006 Anti-inflammatory MAS825 MAS825 MHV370 MHV370 VAY736 ianalumab BAFF-R inhibitor Neuroscience Code Name ADPT06 ADPT06 Mechanism BLZ945 DLX313 LMI070 sotuletinib DLX313 (UCB0599) branaplam CSF-1R inhibitor Alpha-synuclein Inhibitor mRNA splicing modulator MIJ821 MIJ821 NR2B negative allosteric modulator 39 Investor Relations | Q1 2022 Results Hematology Appendix Innovation: Clinical trials References Abbreviations 30 lead indications Lead indication Mechanism BCR-ABL inhibitor Code ABL001 ScemblixⓇ INC424 Jakavi® Name JAK1/2 inhibitor LNP023 iptacopan CFB inhibitor MBG453 sabatolimab PHE885 PHE885 PKC412 Rydapte TIM3 antagonist BCMA cell therapy Multi-targeted kinase inhibitor Cardiovascular, Renal, Metabolism Code Name CFZ533 iscalimab Mechanism CD40 inhibitor HSY244 HSY244 LNP023 iptacopan MBL949 MBL949 CFB inhibitor Indication(s) Chronic myeloid leukemia, 2L, pediatrics Myelofibrosis (combo) Autoimmune cytopenias Unfit acute myeloid leukaemia Acute GVHD, pediatrics Chronic GVHD, pediatrics Acute myeloid leukaemia, maintenance 4L multiple myeloma Acute myeloid leukemia, pediatrics Indication(s) Lupus nephritis Type 1 diabetes mellitus Atrial fibrillation Membranous nephropathy Obesity related diseases. Osteoarthritis Acne Osteoarthritis (combos) Colitis ulcerative Hidradenitis suppurativa Hidradenitis suppurativa NLRC4-GOF indications Sjögren's Sjögren's Systemic lupus erythematosus Indication(s) Cognitive impairment Amyotrophic lateral sclerosis Parkinson's disease Huntington's disease Mixed connective tissue disease Autoimmune hepatitis Major depressive disorder with acute suicidal ideation or behavior Others Code Name Global Health KAE609 cipargamin KAF156 ganaplacide LXE408 LXE408 SEG101 Adakveo® Respiratory & Allergy CMK389 CSJ117 CMK389 ecleralimab QBW251 icenticaftor QMF149 Atectura® Ophtalmology CPK850 CPK850 LKA651 LKA651 PPY988 PPY988 SAF312 libvatrep UNR844 UNR844 Mechanism PfATP4 inhibitor Proteasome inhibitor P-selectin inhibitor IL-18 inhibitor TSLP inhibitor CFTR potentiator Combo RLBP1 AAV EPO inhibitor Gene therapy TRPV1 antagonist Reduction of disulfide bonds Indication(s) Malaria, severe Malaria, uncomplicated Visceral leishmaniasis Malaria, uncomplicated Sickle cell anaemia with crisis, pediatrics Pulmonary sarcoidosis Asthma Chronic obstructive pulmonary disease Bronchiectasis Chronic obstructive pulmonary disease Asthma, pediatrics Retinitis pigmentosa Diabetic retinopathy Geographic atrophy Chronic ocular surface pain Presbyopia U NOVARTIS | Reimagining Medicine#40Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis pipeline in Phase 3 Solid Tumors Hematology Appendix Innovation: Clinical trials References Abbreviations 8 lead indications Lead indication Code AAA617 Name Mechanism Indication(s) Code Name PluvictoⓇ Radioligand therapy target PSMA mCRPC, pre-taxane ABL001 Scemblix AAA6011) Lutathera® ACZ885 canakinumab IL-1b inhibitor Metastatic hormone sensitive prostate cancer (mHSPC) Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3 tumors (GEP-NET 1L G3) NSCLC, adjuvant CTL019 ETB115 KymriahⓇ Promacta® LNP023 iptacopan CFB inhibitor BYL719 Piqray® PI3Ka inhibitor HER2+ adv BC Triple negative breast cancer Ovarian cancer DRB436 Tafinlar +Mekinist® BRAF inhibitor + MEK inhibitor Thyroid cancer MBG453 YTB323 sabatolimab YTB323 TIM3 antagonist CD19 CAR-T Mechanism BCR-ABL inhibitor CD19 CAR-T Thrombopoietin receptor (TPO-R) agonist Indication(s) Chronic myeloid leukemia, 1st line 1L high risk acute lymphocytic leukaemia, pediatrics & young adults Radiation sickness syndrome Paroxysmal nocturnal haemoglobinuria Atypical haemolytic uraemic syndrome Myelodysplastic syndrome 2L Diffuse large B-cell lymphoma³) INC280 Tabrecta® Met inhibitor Non-small cell lung cancer JDQ443 JDQ443 KRAS inhibitor 2/3L Non-small cell lung cancer LEE011 Kisqali® CDK4 Inhibitor NIS793 NIS793 TGFB1 inhibitor VDT482 Tislelizumab PD1 inhibitor HR+/HER2- BC (adj) 1L Nasopharyngeal Carcinoma 1L ESCC 1L Metastatic pancreatic ductal adenocarcinoma Adj/Neo adj. NSCLC 1L Hepatocellular Carcinoma 1L Gastric cancer Localized ESCC Code Name KJX839 Leqvio® LCZ696 EntrestoⓇ LNP023 iptacopan Cardiovascular, Renal, Metabolism Mechanism siRNA (regulation of LDL-C) Angiotensin receptor/neprilysin inhibitor CFB inhibitor Indication(s) CVRR-LDLC Hyperlipidemia, pediatrics Congestive heart failure, pediatrics²) IgA nephropathy 1L Urothelial Cell Carcinoma 1L Small Cell Lung Cancer TQJ230 Pelacarsen ASO targeting Lp(a) C3 glomerulopathy Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a) (CVRR-Lp(a)) Immunology Code Name Mechanism AIN457 Cosentyx® IL17A inhibitor LOU064 remibrutinib VAY736 ianalumab Others Indication(s) Lupus Nephritis Axial SpA (IV formulation) Giant cell arteritis Hidradenitis suppurativa Code Name Mechanism Indication(s) Psoriatic arthritis (IV formulation) Global Health COA566 Coartem® Malaria, uncomplicated (<5kg patients) BTK inhibitor Chronic spontaneous urticaria Respiratory & Allergy IGE025 XolairⓇ BAFF-R inhibitor Lupus Nephritis³) IgE inhibitor Food allergy Auto-injector IgE inhibitor Neuroscience Code Name AMG334 AimovigⓇ BAF312 MayzentⓇ LOU064 remibrutinib OAV101 AVXS-101 OMB157 KesimptaⓇ Mechanism CGRPR antagonist S1P1,5 receptor modulator BTK inhibitor Indication(s) Migraine, pediatrics Multiple sclerosis, pediatrics Multiple sclerosis SMN1 gene replacement therapy SMA IT administration CD20 Antagonist Multiple sclerosis, pediatrics QGE031 ligelizumab Ophthalmology RTH258 Beovu® VEGF inhibitor Food allergy Diabetic retinopathy Biosimilars Code GP2411 Name denosumab SOK583 aflibercept Mechanism anti RANKL mAb VEGF inhibitor Indication(s) Osteoporosis (same as originator) Ophthalmology indication (as originator) 1. 177 Lu-dotatate in US. 2. Approved in US. 3. Ph3 to be initiated in 2022. 40 Investor Relations | Q1 2022 Results U NOVARTIS | Reimagining Medicine#41Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis pipeline in registration Solid Tumors Code VDT482 Name Others Code Mechanism Indication(s) tislelizumab PD1 inhibitor 2L ESCC Non-small cell lung cancer Name Mechanism Global Health Indication(s) SKO136 ensovibep Multi-specific DARPin Corona virus infection Appendix Innovation: Clinical trials Hematology Code CTL019 Name KymriahⓇ INC424 Jakavi® References Abbreviations 2 lead indications Lead indication Mechanism CD19 CAR-T JAK1/2 inhibitor Indication(s) r/r Follicular lymphoma Acute GVHD Chronic GVHD 41 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#42NEW INDICATIONS Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis submission schedule New Molecular Entities: Lead and supplementary indications LEAD INDICATIONS 2022 2023 sabatolimab¹ Lead MBG453 HR-MDS iptacopan LNP023 PNH ensovibep Lead SKO136 COVID19 tislelizumab VDT482 1L Nasopharyngeal Carcinoma tislelizumab VDT482 NSCLC Appendix Innovation: Clinical trials References Abbreviations 2024 2025 ≥2026 Lead JDQ443 JDQ443 Lead icenticaftor Lead 177 Lu-NeoB Lead ganaplacide Lead MIJ821 Lead QBW251 AAA603 KAF156 Acute depression 2/3L NSCLC (mono) COPD Multiple Solid Tumors Malaria uncomplicated remibrutinib Lead ligelizumab Lead branaplam Lead iscalimab Lead LOU064 QGE031 LMI070 CFZ533 PPY988 Geographic atrophy Lead CSU Food allergy Huntington's disease Sjögren's syndrome UNR844 Presbyopia Lead NIS793 Lead cipargamin Lead ianalumab Lead TNO155 Lead 1L Pancreatic cancer KAE609 VAY736 Solid tumors Malaria severe Sjögren's syndrome pelacarsen Lead CPK850 Lead libvatrep Lead tropifexor&licogliflozi Lead TQJ230 RP SAF312 LJN452 COSP NASH (combos) CVRR-Lp(a) YTB323 Lead ecleralimab Lead LNA043 Lead 2L Diffuse large B-cell lymphoma CSJ117 Asthma Knee osteoarthritis gevokizumab Lead LXE408 Lead VPM087 Visceral leishmaniasis 1st line CRC LCM Pluvicto LCM Pluvicto LCM Scemblix LCM Scemblix LCM ianalumab LCM remibrutinib LCM AAA617 AAA617 ABL001 ABL001 VAY736 LOU064 MHSPC CML 1L CML, 2L, pediatrics Lupus Nephritis Pre-taxane Sjögren's syndrome LCM iptacopan LCM sabatolimab LCM iptacopan LCM cipargamin LCM ianalumab LCM tislelizumab LCM LNP023 MBG453 C3G Unfit AML LNP023 aHUS KAE609 VAY736 VDT482 Malaria uncomplicated SLE Adj/Neo adj NSCLC iptacopan LCM tislelizumab LCM remibrutinib LCM JDQ443 LCM iscalimab LCM tislelizumab LCM VDT482 LNP023 IgAN 1L Small Cell Lung Cancer LOU064 Multiple sclerosis JDQ443 CFZ533 VDT482 NSCLC (combo) Liver Tx 1L Urothelial Cell Carcinoma tislelizumab LCM ianalumab LCM VAY736 iptacopan LNP023 LCM VDT482 1L Gastric Cancer AIH iMN tislelizumab LCM VDT482 1L ESCC tislelizumab LCM VDT482 Localized ESCC tislelizumab LCM VDT482 1L Hepatocellular Carcinoma 1. Filing opportunity in 2022 / 2023, based on PFS and/or OS outcomes from a dual approach based on parallel Phase 2 and Phase 3 trials. 42 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#43Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis submission schedule Supplementary indications for existing brands Appendix Innovation: Clinical trials References Abbreviations 2022 2023 2024 2025 ≥2026 Cosentyx LCM canakinumab LCM Adakveo LCM aflibercept BioS Atectura LCM Kesimpta³ LCM Rydapt LCM secukinumab, AIN457 ACZ885 SEG101 SOK583 PSA IV Adjuvant NSCLC Sickle cell anaemia with crisis ped Neovascular age-related macular degeneration indacaterol + mometasone, QMF149 Asthma, pediatrics ofatumumab midostaurin, PKC412 Multiple sclerosis, pediatrics Acute myeloid leukemia, pediatrics Cosentyx LCM Cosentyx LCM Coartem LCM Beovu LCM Aimovig LCM Kymriah LCM Tabrecta LCM secukinumab, AIN457 secukinumab, AIN457 Hidradenitis suppurativa axSpA IV artemether + lumefantrine, COA566 Malaria uncompl., formula for <5kg brolucizumab, RTH258 erenumab, AMG334 tisagenlecleucel, CTL019 capmatinib, INC280 Diabetic retinopathy Pediatric Migraine 1L high risk ALL, pediatrics & young adults NSCLC Entresto EU1 LCM denosumab BioS Cosentyx LCM Cosentyx LCM Cosentyx LCM Leqvio LCM sacubitril/valsartan, LCZ696 GP2411 secukinumab, AIN457 secukinumab, AIN457 secukinumab, AIN457 KJX839 Pediatric CHF anti RANKL mAb GCA Lichen Planus Lupus Nephritis CVRR-LDLC Tafinlar + Mekinist LCM Kisqali LCM Jakavi LCM Leqvio LCM Jakavi LCM Mayzent4 LCM dabrafenib + trametinib, DRB436 ribociclib, LEE011 ruxolitinib, INC424 KJX839 ruxolitinib, INC424 siponimod, BAF312 HGG/LGG - Pediatrics. HR+/HER2- BC (adj) Pediatrics Acute GVHD Ped Hyperlipidemia Myelofibrosis (combination) Multiple sclerosis, pediatrics Xolair LCM Lutathera LCM Jakavi LCM Piqray LCM omalizumab, IGE025 177Lu-oxodotreotide² ruxolitinib, INC424 alpelisib, BYL719 Auto-injector GEP-NET 1L G3 Pediatrics Chronic GVHD HER2+ adv BC Piqray LCM Tafinlar + Mekinist LCM Promacta LCM alpelisib, BYL719 TNBC dabrafenib + trametinib, DRB436 Thyroid cancer eltrombopag, ETB115 Radiation sickness syndrome Piqray LCM Zolgensma LCM alpelisib, BYL719 AVXS-101 OAV101 Ovarian cancer SMA IT Xolair LCM omalizumab, IGE025 Food allergy 1. Approved in US. 2. 177Lu-dotatate in US. 3. Kesimpta and Mayzent: pediatric study in multiple sclerosis run in conjunction (NEOS). 43 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#44Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors Clinical Trials Update Includes selected ongoing or recently concluded global trials of Novartis development programs/products which are in confirmatory development or marketed (typically Phase 2b or later). For further information on all Novartis clinical trials, please visit: www.novartisclinicaltrials.com References Abbreviations Hematology Biosimilars Global Health 44 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#45Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Cardiovascular, Renal and Metabolic 45 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#46Company overview CRM Financial performance Immunology Financial review Neuroscience EntrestoⓇ - 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors References Abbreviations Hematology Biosimilars Angiotensin receptor/neprilysin inhibitor Global Health Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT02678312 PANORAMA HF (CLCZ696B2319) Heart failure in pediatric patients Phase 3 377 Part 1: Pharmacodynamics and pharmacokinetics of sacubitril/valsartan LCZ696 analytes Part 2: Efficacy and safety compared with enalapril Part 1: Sacubitril/valsartan 0.8 mg/kg or 3.1 mg/kg or both; 0.4 mg/kg or 1.6 mg/kg or both (single doses). Part 2: enalapril/placebo 0.2 mg/kg bid (ped. formulation 1mg/ml) and adult formulation (2.5, 5, 10 mg bid); Sacubitril/valsartan (LCZ696)/placebo: Ped. formulation granules (12.5, 31.25 mg in capsules); liquid formulation (1mg/ml and 4mg/ml concentration) and adult formulation (50, 100, 200 mg bid) Pediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction NCT02884206 PERSPECTIVE (CLCZ696B2320) Heart failure Phase 3 592 Change from baseline in the CogState Global Cognitive Composite Score (GCCS) Sacubitril/valsartan 50, 100, and 200 mg bid with placebo of valsartan Valsartan 40, 80, and 160 mg bid tablets with placebo for sacubitril/valsartan Patients with chronic heart failure with preserved ejection fraction Target Patients Read-out Milestone(s) 2022; (Analysis of 110 pts from Part 2 formed the basis for pediatric submission in Apr-2019 and approval by the US FDA in Oct-2019 for the treatment of symptomatic HF with systemic left ventricular systolic dysfunction in children aged 1 year and older) 2023 Publication TBD TBD 46 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#47Company overview Financial review Financial performance CRM Immunology Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors References Abbreviations Hematology Biosimilars Global Health Entresto® - Angiotensin receptor/neprilysin inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03785405 (CLCZ696B2319E1 - extension study) Heart failure in pediatric patients Phase 3 240 Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Single arm, open label sacubitril/valsartan (pediatric formulation granules (12.5, 31.25 mg in capsules); liquid formulation (1mg/ml and 4mg/ml concentration) and adult formulation (50, 100, 200 mg bid)) Pediatric patients with heart failure due to systemic left ventricle systolic dysfunction who have completed study CLCZ696B2319 Target Patients Read-out Milestone(s) 2023 Publication TBD 47 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#48Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors Leqvio®-siRNA (regulation of LDL-C) Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03705234 ORION-4 (CKJX839B12301) Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolaemia (HeFH) Phase 3 ~15000 A composite of major adverse cardiovascular events, defined as: Coronary heart disease (CHD) death; Myocardial infarction; Fatal or non-fatal ischaemic stroke; or Urgent coronary revascularization procedure Arm 1: every 6 month treatment Inclisiran sodium 300mg (given by subcutaneous injection on the day of randomization, at 3 months and then every 6- months) for a planned median duration of about 5 years Arm 2: matching placebo (given by subcutaneous injection on the day of randomization, at 3 months and then every 6-months) for a planned median duration of about 5 years. Patient population with mean baseline LDL-C >= 100mg/dL Read-out Milestone(s) 2026 Publication TBD 48 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine#49Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health LeqvioⓇ - siRNA (regulation of LDL-C) Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT03060577 ORION-3 (CKJX839A12201E1) Hypercholesterolemia inc. Atherosclerotic Cardiovascular Disease (ASCVD) and ASCVD risk equivalents Heterozygous Familial Hypercholesterolaemia (HeFH) Phase 2 490 LDL-C reduction at Day 210 for Group 1 subjects Changes in other lipids and lipoproteins and reduction of LDL-C of more than 50% for patients that are above LDL-C goal; longer term exposure and safety. Group 1 - inclisiran sodium 300mg sc on Day 1 and every 180 days thereafter for up to 4 years. Group 2- Evolocumab 140mg s.c. injection on Day 1 and every 2 weeks until Day 336, followed by inclisiran sodium 300mg on Day 360, Day 450 and then every 6 months for a planned duration of 4 years. Patients with HeFH or pre-existing atherosclerotic cardiovascular disease (ASCVD) on background statin +/- ezetimibe therapy H1-2022 TBD NCT03814187 ORION-8 (CKJX839A12305B) Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolaemia (HeFH) and Homozygous Familial Hypercholesterolemia (HoFH) Phase 3 2991 Proportion of subjects achieving pre specified low density lipoprotein cholesterol (LDL-C) targets at end of study Safety and tolerability profile of long term use of inclisiran Inclisiran sodium 300mg on day 1 (placebo patients entered into study from ORION 9, 10 & 11) or placebo on Day 1 (inclisiran patients entered into study from ORION 9, 10 & 11) then inclisiran sodium 300mg on Day 90 and every 6 months for a planned duration of 3 years Patients with HeFH or pre-existing atherosclerotic cardiovascular disease (ASCVD) on background statin +/- ezetimibe therapy and risk equivalents (patients from ORION 3, 9, 10 & 11 studies) 2023 TBD 49 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#50Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health LeqvioⓇ - siRNA (regulation of LDL-C) Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT03851705 ORION-5 (CKJX839A12302) Hypercholesterolemia inc. Homozygous Familial Hypercholesterolemia (HoFH) Phase 3 56 LDL-C reduction at Day 150 Changes in PCSK9, other lipids and lipoproteins Part 1: inclisiran sodium 300mg on Day 1 and Day 90 or placebo on Day 1 and Day 90 Part 2: inclisiran sodium 300mg on Day 180 for patients who were randomized to the placebo group only, inclisiran sodium 300mg on Day 270 and then every 6 months for a planned duration of 2 years for all patients Patients with HoFH with background statin +/- ezetimibe therapy Primary: Q3-2020 (actual); Final: H2-2021 TBD NCT04652726 ORION-16 (CKJX839C12301) Hyperlipidemia, pediatrics Phase 3 150 Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630; Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C) 2025 TBD 50 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#51Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health LeqvioⓇ - siRNA (regulation of LDL-C) Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT04659863 ORION-13 (CKJX839C12302) Hyperlipidemia, pediatrics Phase 3 15 Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630;Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C) NCT05030428 VICTORION-2P (CKJX839B12302) CVRR Phase 3 15000 1. Time to First Occurrence of 3P-MACE (3-Point Major Adverse Cardiovascular Events) Arm 1: Experimental Inclisiran sodium, Subcutaneous injection Arm 2: Placebo Comparator, Placebo Subcutaneous injection Participants with established cardiovascular disease (CVD) Read-out Milestone(s) 2025 Publication TBD 51 Investor Relations | Q1 2022 Results 2027 TBD 1 NOVARTIS | Reimagining Medicine#52Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology iptacopan - CFB inhibitor Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health NCT03955445 (CLNP023B12001B) C3 glomerulopathy (C3G) Phase 2 Study Indication Phase Patients Primary Outcome Measures NCT04817618 APPEAR-C3G (CLNP023B12301) C3 glomerulopathy Phase 3 68 27 Log-transformed ratio to baseline in UPCR (sampled from a 24 hour urine collection) Arms Intervention Experimental: iptacopan 200mg b.i.d. Placebo Comparator: Placebo to iptacopan 200mg b.i.d. Patients with native C3G Target Patients Read-out Milestone(s) 2023 Publication TBD 52 Investor Relations | Q1 2022 Results Characterize the effect of LNP023 treatment on a composite renal response endpoint at 9 months (1. a stable or improved eGFR and, 2. a reduction in proteinuria and 3. an increase in C3 compared to the CLNP023X2202 baseline visit) Open-label LNP023 200mg bid Patients with C3 glomerulopathy 2025 Wong et al 2021 Nephrology, Dialysis and Transplantation Vol. 36, Suppl. 1: eGFR trajectory 1 NOVARTIS | Reimagining Medicine#53Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology iptacopan - CFB inhibitor Study Indication Phase NCT04154787 (CLNP023D12201) Idiopathic membranous nephropathy (iMN) Phase 2 Patients 72 Primary Outcome Measures Arms Intervention Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health NCT04578834 APPLAUSE-IgAN (CLNP023A2301) IgA nephropathy Phase 3 450 Change from baseline of UPCR derived from 24hr urine collections at Baseline and Week 24 Ratio to baseline in urine protein to creatinine ratio (sampled from 24h urine collection) at 9 months Annualized total estimated Glomerular Filtration Rate (eGFR) slope estimated over 24 months Arm 1 - LNP023 200mg BID Arm 2 - Placebo BID Target Patients Read-out Milestone(s) 2023 Publication TBD 53 Investor Relations | Q1 2022 Results LNP023 low dose LNP023 high dose Rituximab Patients with biopsy proven iMN who are at high risk of disease progression defined on the basis of antibody anti-PLA2R titre and proteinuria Primary IgA Nephropathy patients 2023 (primary endpoint for US initial submission, 9 months UPCR)2025 (24 months) Perkovic et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1: Study Design Wong et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1: IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY U NOVARTIS | Reimagining Medicine#54Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Ophthalmology Respiratory & Allergy Oncology: Solid Tumors pelacarsen - ASO targeting Lp(a) Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04023552 Lp(a) HORIZON (CTQJ230A12301) Cardiovascular risk reduction Phase 3 7680 Time to the first occurrence of MACE (cardiovascular death, non-fatal MI, non-fatal stroke and urgent coronary re-vascularization) TQJ230 80 mg injected monthly subcutaneously or matched placebo Patients with a history of Myocardial infarction or Ischemic Stroke, or a clinically significant symptomatic Peripheral Artery Disease, and Lp(a) >= 70 mg/dL Target Patients Read-out Milestone(s) 2025 Publication TBD References Abbreviations Hematology Biosimilars Global Health 54 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#55Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Immunology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health 55 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#56Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health LNA043- ANGPTL3 agonist Study Indication Phase Patients Primary Outcome Measures NCT03275064 (CLNA043X2202) Knee osteoarthritis Phase 2 133 Articular cartilage bi-layer collagen organisation evaluated with MRI and measured in milliseconds (ms) (Part A only) Number of patients with any adverse events, serious adverse events and death (Part A and Part B) Change in cartilage volume/thickness in the index region (Part B only) NCT04864392 ONWARDS (CLNA043A12202) Knee osteoarthritis Phase 2 550 Change from baseline in the cartilage thickness of the medial compartment of the knee as assessed by imaging Arms Intervention LNA043 40 mg Part B LNA043 20 mg Part B LNA043 20 mg Part A Placebo Part A Placebo Part B LNA043 injection to the knee with dosing regimen A LNA043 injection to the knee with dosing regimen B LNA043 injection to the knee with dosing regimen C LNA043 injection to the knee with dosing regimen D Placebo injection to the knee Target Patients Patients with cartilage lesions of the knee (Part A) and knee osteoarthritis (Part B) Read-out Milestone(s) 2022 Patients with Symptomatic knee osteoarthritis Primary 2024 Publication TBD TBD 56 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#57Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Cosentyx® - IL-17A inhibitor Study Indication Phase Patients NCT03031782 (CAIN457F2304) JPSA & ERA Phase 3 80 Primary Outcome Measures Time to 33 flares Arms Intervention Secukinumab (pre-filled syringe) 75 mg Placebo Juvenile idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis Target Patients Read-out Milestone(s) H1-2021 Publication H2-2021 NCT03259074 SURPASS (CAIN457K2340) JPSA & ERA Phase 3 837 No radiographic structural progression as measured by modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) Secukinumab 150/300 mg Adalimumab biosimilar 40 mg Patients with active ankylosing spondylitis 2022 Study design manuscript published. Baraliakos et al. Clinical Drug Investigation (2020) 40:269-278. 57 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#58Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT03713619 SUNSHINE (CAIN457M2301) Hidradenitis Suppurativa (HS) Phase 3 471 Proportion of participants with Hidradenitis Suppurativa clinical response (HiSCR) Secukinumab 300 mg every 2 weeks Secukinumab 300 mg every 4 weeks Placebo (every 2 weeks) Placebo (every 4 weeks) Patients with moderate to severe Hidradenitis Suppurativa Primary (week 16): H2-2021; Final: H2-2022 Study design SHSA 2020; Primary H2-2022 NCT03713632 SUNRISE (CAIN457M2302) Hidradenitis Suppurativa (HS) Phase 3 471 Proportion of patients with Hidradenitis Suppurativa Clinical Response (HiSCR) Secukinumab 300 mg every 2 weeks Secukinumab 300 mg every 4 weeks Placebo (every 2 weeks) Placebo (every 4 weeks) Subjects with moderate to severe Hidradenitis Suppurativa Primary (week 16): H2-2021; Final: 2022 Study design SHSA 2020; Primary 2022 58 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#59Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03769168 (CAIN457F2304E1 - extension study) Psoriatic arthritis Phase 3 64 Number of participants with JIA ACR30 response Secukinumab 75 mg/0.5 ml Secukinumab 150 mg/1.0 ml Patients with juvenile idiopathic arthritis subtypes of juvenile psoriatic arthritis and enthesitis related arthritis Target Patients Read-out Milestone(s) 2025 Publication TBD NCT04156620 INVIGORATE-1 (CAIN457P12301) Axial spondyloarthritis Phase 3 500 The proportion of subjects achieving an ASAS40 (Assessment of SpondyloArthritis International Society criteria) response Secukinumab intravenous (i.v.) regimen Placebo intravenous (i.v.) regimen Patients with active axial spondyloarthritis Primary (week 16): 2022; Final: 2023 2023 59 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#60Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04179175 (CAIN457M2301E1) Hidradenitis Suppurativa (HS) Phase 3 745 Proportion of patients with Hidradenitis Suppurativa Clinical Response (HiSCR) Secukinumab 300 mg every 2 weeks Secukinumab 300 mg every 4 weeks Patients with moderate to severe hidradenitis suppurativa completing either of the core trials AIN457M2301 (NCT 0313632) or AIN567M2302 (NCT03713619) Target Patients Read-out Milestone(s) 2025 Publication Study design SHSA 2020 NCT04181762 SELUNE (CAIN457Q12301) Lupus Nephritis Phase 3 460 Proportion of subjects achieving protocol-defined CRR Secukinumab 300 mg s.c. Placebo s.c. Patients with active lupus nephritis (ISN/RPS Class III or IV, with or without co- existing class V features) 2026 2026 60 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#61Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04209205 INVIGORATE-2 (CAIN457P12302) Psoriatic Arthritis (PSA) Phase 3 380 The proportion of subjects achieving American College of Rheumatology 50 (ACR50) response criteria Secukinumab intravenous (i.v.) regimen Placebo intravenous (i.v.) regimen Patients with active psoriatic arthritis (PSA) despite current or previous NSAID, DMARD and/or anti-TNF therapy Target Patients Read-out Milestone(s) Publication 2023 H2-2021 (Actual) NCT04300296 PRELUDE (CAIN457S12201) Lichen Planus Phase 2 108 Proportion of patients achieving Investigator's Global Assessment (IGA 0/1) score at 16 weeks +30% delta vs placebo Secukinumab 300 mg s.c. Placebo s.c. Adult patients with biopsy-proven lichen planus not adequately controlled by topical therapies 2022 TBD 61 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#62Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures NCT04930094 (CAIN457R12301) Giant cell arteritis Phase 3 240 Arms Intervention Target Patients Read-out Milestone(s) Publication Number of participants with sustained remission Experimental: Secukinumab 300 mg Placebo Comparator: Placebo Patients with Giant Cell Arteritis (GCA) Primary 2024 Final 2025 TBD References Abbreviations Hematology Biosimilars Global Health 62 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#63Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors ianalumab - BAFF-R inhibitor Study Indication Phase Patients Primary Outcome Measures NCT03217422 AMBER (CVAY736B2201) Autoimmune hepatitis Phase 2 80 Alanine aminotransferase (ALT) normalization Arms Intervention VAY736 Placebo control with conversion to active VAY736 Autoimmune hepatitis patients with incomplete response or intolerant to standard treatment of care Target Patients Read-out Milestone(s) 2026 Publication TBD References Abbreviations Hematology Biosimilars Global Health 63 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#64Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health iscalimab - CD40 inhibitor Study Indication Phase NCT03781414 CONTRAIL I (CCFZ533A2202) Liver transplantation Phase 2 Patients 128 NCT03905525 TWINSS (CCFZ533B2201) Sjögren's syndrome Phase 2 260 Primary Outcome Measures Arms Intervention Proportion of patients with composite event (BPAR, Graft Loss or Death) over 12 months Control/Standard of Care: TAC + MMF + Corticosteroids CFZ533 dose A+ MMF + Corticosteroids CFZ533 dose B + MMF + Corticosteroids Liver transplant recipients Change in EULAR Sjögren's syndrome Disease Activity Index (ESSDAI) score and EULAR Sjögren's syndrome Patient Reported Index (ESSPRI) score Three dose arms of CFZ533 Placebo Target Patients Read-out Milestone(s) 2023 Publication 2023 Patients with Sjögren's syndrome 2022 2022 64 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#65Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Ophthalmology Respiratory & Allergy Oncology: Solid Tumors iscalimab - CD40 inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT04541589 TWINSS Extn (CFZ533B2201E1) Sjögren's syndrome Phase 2 Incidence of Treatment-emergent AES (TEAEs) Change in laboratory evaluations for hematology from baseline to each study visit Change in laboratory evaluations for serum chemistry from baseline to each study visit Change in vital sign measurements from baseline for each post-baseline visit Arm 1 Iscalimab Dose 1 s.c. Q2W Arm 2 Iscalimab Dose 2 s.c. Q2W and Placebo Patients with Sjögren's Syndrome, who participated in the TWINSS core study, CCFZ533B2201(NCT03905525) Primary completion date: 2024 65 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine#66Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors remibrutinib - BTK inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04109313 (CLOU064A2201E1) Chronic spontaneous urticaria (CSU) Phase 2 250 Long-term safety and tolerability Selected dose of LOU064 taken orally twice a day (morning and evening) from day 1 to week 52 Patients with CSU who have participated in preceding studies with LOU064 Target Patients Read-out Milestone(s) H2 2022 Publication Primary: 2023 References Abbreviations Hematology Biosimilars Global Health 66 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#67Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health remibrutinib - BTK inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT05030311 REMIX-1 (CLOU064A2301) Chronic spontaneous urticaria (CSU) Phase 3 450 1. Change from baseline in UAS7 (Scenario 1 with UAS7 as primary efficacy endpoint) 2. Absolute change in ISS7 and absolute change in HSS7 (Scenario 2 with ISS7 and HSS7 as co-primary efficacy endpoints) Arm 1: LOU064 (blinded) LOU064 (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomized in a 2:1 ratio (arm 1:arm 2). Arm 2: LOU064 placebo (blinded) LOU064 placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open- label) taken orally for 28 weeks. Randomized in a 2:1 ratio (arm 1:arm 2) Adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in comparison to placebo Target Patients Read-out Milestone(s) Publication 2024 TBD NCT05032157 REMIX-2 (CLOU064A2302) Chronic spontaneous urticaria (CSU) Phase 3 450 1. Change from baseline in UAS7 (Scenario 1 with UAS7 as primary efficacy endpoint) 2. Absolute change in ISS7 an absolute change in HSS7 (Scenario 2 with ISS7 and HSS7 as co-primary efficacy endpoints) Arm 1: LOU064 (blinded) LOU064A (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open- label) taken orally open label for 28 weeks. Randomised in 2:1 ratio (active vs placebo) Arm 2: LOU064 placebo (blinded) LOU064A placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open- label) taken orally open label for 28 weeks. Randomised in 2:1 ratio (active vs placebo) Adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in comparison to placebo 2024 TBD 67 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#68Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors References Abbreviations Hematology Biosimilars Global Health tropifexor, licogliflozin - FXR agonist and SGLT 1/2 inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04065841 ELIVATE (CLJN452D12201C) Non-alcoholic steatohepatitis (NASH) Phase 2 380 Proportion of patients with resolution of NASH and no worsening of fibrosis OR improvement in fibrosis by at least one stage without worsening of NASH at Week 48 compared with baseline Arm A: combination therapytropifexor + licogliflozin Arm B: tropifexor monotherapytropifexor + licogliflozin placebo Arm C: licogliflozin monotherapylicogliflozin + tropifexor placebo Arm D: licogliflozin placebo + tropifexor placebo Adult patients with biopsy based non-alcoholic steatohepatitis (NASH) and liver fibrosis Target Patients Read-out Milestone(s) Publication 2024 2025 68 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#69Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Neuroscience Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health 69 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#70Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors References Abbreviations Hematology Biosimilars Global Health MIJ821- NR2B negative allosteric modulator (NAM) Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04722666 (CMIJ821A12201) Major depressive disorder with acute suicidal ideation or behavior Phase 2 195 Change from baseline to 24 hours in the total score of the Montgomery Åsberg Depression Rating Scale (MADRS) MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1 or 0.9% sodium chloride Participants who have suicidal ideation with intent Target Patients Read-out Milestone(s) Publication 2023 TBD 70 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#71Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Ophthalmology Respiratory & Allergy Oncology: Solid Tumors AimovigⓇ - CGRP receptor antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT03867201 DRAGON (CAMG334A2304) Migraine Phase 3 550 Change from baseline in monthly migraine days during the last 4 weeks of the 12- week treatment period Subcutaneous injection of AMG334 (erenumab) 70 mg Subcutaneous injection of placebo Adult chronic migraine patients Double-blind FIR for 100% of pts 2021; Q4 2021(actual) Extension (open-label): 2024 Planned in H2-2022 for double-blind phase and H1-2025 for open-label extension phase 71 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine#72Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors LMI070 - mRNA splicing modulator Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT05111249 VIBRANT-HD (CLMI070C12203) Huntington's disease Phase 2 75 1. Reduction (%) of mHTT protein in cerebrospinal fluid (CSF) 2. Number of treatment emergent adverse events and serious adverse events Arm 1: Experimental; Branaplam 56 mg oral solution once weekly Arm 2: Experimental; Branaplam 112 mg oral solution once weekly Arm 3: Experimental; (C) Branaplam 154 mg oral solution once weekly, OR (X) Branaplam 84 mg oral solution once weekly OR (Y) Branaplam 28 mg oral solution once weekly Arm 4: Placebo; Matching placebo oral solution once weekly Participants with early manifest Huntington's Disease Target Patients Read-out Milestone(s) Publication 2025 TBD 72 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine#73Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Ophthalmology Respiratory & Allergy Oncology: Solid Tumors KesimptaⓇ - CD20 antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03650114 ALITHIOS (COMB157G2399) Multiple Sclerosis Phase 3 2010 Evaluate the long-term safety and tolerability of ofatumumab 20 mg subcutaneous (sc) once every 4 (94) weeks in subjects with RMS from the first dose of ofatumumab Ofatumumab 20 mg every 4 weeks Patients with relapsing MS Target Patients Read-out Milestone(s) 2028 Publication TBD References Abbreviations Hematology Biosimilars Global Health 73 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#74Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors MayzentⓇ - S1P1,5 receptor modulator Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT04926818 NEOS (CBAF312D2301) Multiple sclerosis, pediatrics Phase 3 180 Annualized relapse rate (ARR) in target pediatric participants Arm 1: Experimental ofatumumab - 20 mg injection/ placebo Arm 2: Experimental siponimod - 0.5 mg, 1 mg or 2 mg/ placebo Arm 3: Active Comparator fingolimod - 0.5 mg or 0.25 mg/ placebo Children/adolescent patients aged 10-17 years old with Multiple Sclerosis (MS). he targeted enrollment is 180 participants with multiple sclerosis which will include at least 5 participants with body weight (BW) ?40 kg and at least 5 participants with age 10 to 12 years in each of the ofatumumab and siponimod arms. There is a minimum 6 month follow up period for all participants (core and extension). Total duration of the study could be up to 7 years. Read-out Milestone(s) Publication 74 Investor Relations | Q1 2022 Results 2026 TBD References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine#75Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health remibrutinib - BTK inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) NCT05147220 REMODEL-1 (CLOU064C12301) Multiple sclerosis Phase 3 800 Annualized relapse rate (ARR) of confirmed relapses Arm 1: Experimental; Remibrutinib - Core (Remibrutinib tablet and matching placebo of teriflunomide capsule) Arm 2: Active Comparator; Teriflunomide - Core (Teriflunomide capsule and matching placebo remibrutinib tablet) Arm 3: Experimental; Remibrutinib - Extension (Participants on remibrutinib in Core will continue on remibrutinib tablet) Arm 4: Experimental; Remibrutinib - Extension (on teriflunomide in Core) (Participants on teriflunomide in Core will switch to remibrutinib tablet) Patients with relapsing Multiple Sclerosis Estimated primary completion 2025 Estimated study completion 2029 NCT05156281 REMODEL-2 (CLOU064C12302) Multiple sclerosis Phase 3 800 Annualized relapse rate (ARR) of confirmed relapses Arm 1: Experimental; Remibrutinib - Core Remibrutinib tablet and matching placebo of teriflunomide capsule Arm 2: Active Comparator; Teriflunomide - Core Teriflunomide capsule and matching placebo remibrutinib tablet Arm 3: Experimental: Remibrutinib - Extension Participants on remibrutinib in Core will continue on remibrutinib tablet Arm 4: Experimental: Remibrutinib - Extension (on teriflunomide in Core) Participants on teriflunomide in Core will switch to remibrutinib tablet Patients with relapsing Multiple Sclerosis Estimated primary completion 2025 Estimated study completion 2029 Publication 75 Investor Relations | Q1 2022 Results TBD TBD 1 NOVARTIS | Reimagining Medicine#76Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors Hematology ZolgensmaⓇ - SMN1 gene replacement therapy Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT05089656 STEER (COAV101B12301) Spinal muscular atrophy (IT administration) Phase 3 125 1. Change from baseline in Hammersmith functional motor scale - Expanded (HFMSE) total score at the end of follow-up period 1 in treated patients compared to Isham controls in the ≥ 2 to < 18 years age group Arm 1: Experimental OAV101. Administered as a single, one-time intrathecal dose Arm 2: Sham Comparator: Sham control. A skin prick in the lumbar region without any medication. Patients Type 2 Spinal Muscular Atrophy (SMA) who are ≥ 2 to < 18 years of age, treatment naive, sitting, and never ambulatory Target Patients Read-out Milestone(s) Publication 2024 TBD 76 Investor Relations | Q1 2022 Results References Abbreviations Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine#77Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Ophthalmology 77 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#78Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Ophthalmology Respiratory & Allergy Oncology: Solid Tumors UNR844 - Reduction of disulfide bonds Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT04806503 READER (CUNR844A2022) Presbyopia Phase 2B 225 Characterize the dose response relationship among UNR844 doses 0 mg/mL, 5 mg/mL, 13.3 mg/mL, 23 mg/mL and 30 mg/mL dosed twice-daily after Month 3 of dosing. Change from baseline in Binocular distance-corrected near visual acuity at 40 cm at Month 3. 1:1 randomization - UNR844 0 mg/mL, 5 mg/mL, 13.3 mg/mL, 23 mg/mL and 30 mg/mL dosed twice-daily for three months Presbyopic participants aged 45 to 55 years 2022: Primary endpoint- when all patients have completed the 3 months treatment period 2023: Final analysis -Study completion (all patients have completed 9 months pots treatment period) H1-2023 78 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine#79Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology BeovuⓇ - Anti-VEGF Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04005352 TALON (CRTH258A2303) Neovascular Age-related Macular Degeneration (nAMD) Phase 3B 739 Average change in Best-corrected visual acuity Distribution of the last interval with no disease activity (in a Treat-to-Control regimen) Arm 1: Brolucizumab 6 mg intravitreal injection Arm 2: Aflibercept 2 mg intravitreal injection Patients with Neovascular Age-related Macular Degeneration (nAMD) who have not previously received anti-VEGF (vascular endothelial growth factor) treatment Target Patients Read-out Milestone(s) 2022 Publication TBD 79 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine#80Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology BeovuⓇ - Anti-VEGF Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04047472 HOBBY (CRTH258A2307) Macular degeneration Phase 3 494 Change from baseline in best-corrected visual acuity (BCVA) at week 48 Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Chinese patients with neovascular age-related macular degeneration Target Patients Read-out Milestone(s) 2024 Publication TBD References Abbreviations Hematology Biosimilars Global Health 80 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#81Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health BeovuⓇ - VEGF Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03917472 KINGFISHER (CRTH258B2305) Diabetic macular edema Phase 3 500 Change in best-corrected visual acuity (BCVA) from baseline up to week 52 Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Target Patients Patients with visual impairment due to diabetic macular edema Read-out Milestone(s) Q3-2021 (Actual) Publication Publication submission planned for H1-2022 NCT04058067 KINGLET (CRTH258B2304) Diabetic macular edema Phase 3 263 Change in best-corrected visual acuity (BCVA) Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Chinese patients with visual impairment due to diabetic macular edema 2023 Publication planned for 2024 81 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#82Company overview CRM Financial performance Immunology BeovuⓇ - Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology VEGF Inhibitor Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04278417 (CRTH258D2301) Diabetic retinopathy Phase 3 706 Change from Baseline in BCVA Arm1: RTH258 (brolucizumab) 6 mg/50uL Arm2: Panretinal photocoagulation laser initial treatment followed with additional PRP treatment as needed Patients with proliferative diabetic retinopathy Target Patients Read-out Milestone(s) 2024 Publication TBD 82 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health NOVARTIS | Reimagining Medicine#83Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors libvatrep - TRPV1 antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04630158 SAHARA (CSAF312B12201) Chronic ocular surface pain Phase 2 150 Change in mean pain severity Visual Analog Scale Placebo Comparator: SAF312 Placebo. Randomized to a 1:1:1 topical eye drops, twice daily Experimental: SAF312 dose 1. Randomized to a 1:1:1 topical eye drops, twice daily Experimental: SAF312 dose 2. Randomized to a 1:1:1 topical eye drops, twice daily Subjects with CICP persisting at least for 4 months after refractive surgery and chronicity confirmed during the observational period. Target Patients Read-out Milestone(s) Publication 2023 2023 83 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine#84Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Respiratory & Allergy 84 Investor Relations | Q1 2022 Results Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health NOVARTIS | Reimagining Medicine#85Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors CSJ117 - Inhaled TSLP inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04410523 (CCSJ117A12201C) Asthma Phase 2 625 Pre-dose FEV1 (Forced Expiratory Volume in 1 second) change from baseline after 12 weeks of treatment. Average change from baseline in pre-dose FEV1 at week 8 & week 12 CSJ117 0.5mg CSJ117 1mg CSJ117 2 mg CSJ117 4 mg CSJ117 8 mg Placebo Asthma patients on background medium or high ICS plus LABA therapy Target Patients Read-out Milestone(s) 2023 Publication 2023 85 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine#86Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors icenticaftor - CFTR potentiator Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04072887 (CQBW251B2201) Chronic obstructive pulmonary disease (COPD) Phase 2 956 Trough FEV1 (Forced Expiratory Volume in 1 second) change from baseline after 12 weeks of treatment QBW251 450 mg QBW251 300 mg QBW251 150 mg QBW251 75 mg QBW251 25 mg Placebo COPD patients on background triple inhaled therapy (LABA / LAMA / ICS) Target Patients Read-out Milestone(s) Publication 2022 86 Investor Relations | Q1 2022 Results Primary publications planned for 2022 References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine#87Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors ligelizumab - IgE inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04984876 (CQGE031G12301) Food allergy Phase 3 486 1. Proportion of participants who can tolerate a single dose of ≥ 600 mg (1044 mg cumulative tolerated dose) of peanut protein without dose-limiting symptoms at Week 12 Arm 1: Experimental ligelizumab 240 mg subcutaneous injection for 52 weeks Arm 2: Experimental ligelizumab 120 mg subcutaneous injection for 52 weeks Arm 3: Experimental Placebo 8 weeks and ligelizumab 120 mg Arm 4: Placebo subcutaneous injection for first 8 weeks and ligelizumab 120 mg subcutaneous injection for 44 weeks Arm 5: Experimental Placebo 16 weeks and ligelizumab 120 mg/240 mg subcutaneous injection for 36 weeks Arm 6: Experimental Placebo 8 weeks and ligelizumab 240 mg subcutaneous injection for 44 weeks Participants with a medically confirmed diagnosis of IgE-mediated peanut allergy Target Patients Read-out Milestone(s) 2025 Publication TBD 87 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine#88Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Oncology: Solid Tumors 88 Investor Relations | Q1 2022 Results Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health NOVARTIS | Reimagining Medicine#89Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors Vijoyce® - PI3K-alpha inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT04589650 EPIK-P2 (CBYL719F12201) PIK3CA-related overgrowth spectrum Phase 2 174 Proportion of participants with a response at Week 24 Arm 1: alpelisib vs. Arm 2: placebo during the 16 first weeks, for each cohort (adult, pediatric), with placebo patients switching to alpelisib thereafter. Pediatric and adult participants with PIK3CA-related overgrowth spectrum (PROS) Primary Analysis: 2023 NA References Abbreviations Hematology Biosimilars Global Health 89 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#90Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health canakinumab - IL-1 beta inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT03631199 CANOPY-1 (CACZ885U2301) 1st Line Non-small cell lung cancer (NSCLC) Phase 3 627 Safety run-in part: Incidence of dose limiting toxicities Double-blind, randomized, placebo-controlled part: Progression free survival (PFS) Overall survival (OS) Canakinumab or matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy Patients with: Histologically confirmed Stage IIIB, IV NSCLC with no prior systemic anticancer therapy Squamous and non-squamous NSCLC No EGFR mutation and ALK rearrangement H2-2021 Johnson B et al. Presented at AACR-NCI-EORTC 2019 (safety run-in) Planned abstract submission to AACR 2022 90 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#91Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health canakinumab - IL-1beta inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03447769 CANOPY-A (CACZ885T2301) Adjuvant NSCLC Phase 3 1500 Disease free survival (primary), overall survival (key secondary) Canakinumab 200mg q3w sc for 18 cycles Placebo q3w sc for 18 cycles Patients with: High-risk NSCLC (AJCC/UICC v.8 stage II-IIIA and IIIB (T>5cm N2)) after complete resection and standard of care adjuvant cisplatin-based chemotherapy All histologies Read-out Milestone(s) 2022 Publication TBD 91 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#92Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology NIS793 - TGFẞ1 inhibitor Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT04935359 (CNIS793B12301) 1L metastatic pancreatic ductal adenocarcinoma Phase 3 490 Safety run-in part: Percentage of participants with dose limiting toxicities (DLTs) during the first cycle (4 weeks) of treatment Randomized part: Overall survival (OS) Randomized portion of the study: Arm 1: NIS793+gemcitabine+nab-paclitaxel Arm 2: placebo+gemcitabine+nab-paclitaxel Patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), first line treatment Primary 2025 TBD 92 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#93Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health TNO155 - SHP2 inhibitor Study Indication Phase Patients Primary Outcome Measures NCT03114319 (CTNO155X2101) Solid tumors (single agent) Phase 1 255 Number of participants with adverse events Number of participants with dose limiting toxicities Arms Intervention Drug: TNO155 Drug: TNO155 in combination with EGF816 (nazartinib) Adult patients with advanced solid tumors in selected indications Target Patients Read-out Milestone(s) 2023 Publication TBD 93 Investor Relations | Q1 2022 Results NCT04000529 (CTNO155B12101) Solid tumors (combo) Phase 1 126 Incidence of dose limiting toxicities (DLTs) during the first cycle of combination treatment during the dose escalation part Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as per CTCAE v5.0, by treatment Dose tolerability TNO155 and Spartalizumab (PDR001) TNO155 and Ribociclib (LEE011) Patients with advanced malignancies 2022 TBD NOVARTIS | Reimagining Medicine#94Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health PluvictoⓇ- Radioligand therapy target PSMA Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) NCT04689828 PSMAfore (CAAA617B12302) Metastatic castration-resistant prostate cancer, pre-taxane Phase 3 450 Radiographic Progression Free Survival (rPFS) Arm 1: Participants will receive 7.4 GBq (200 mCi) +/- 10% lutetium (177Lu) vipivotide tetraxetan once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used Arm 2: For participants randomized to the ARDT arm, the change of ARDT treatment will be administered per the physician's orders. Best supportive care, including ADT may be used mCRPC patients that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or MHSPC settings Primary Analysis: 2022 Final Analysis: 2025 NCT04720157 PSMAddition (CAAA617C12301) Metastatic hormone sensitive prostate cancer Phase 3 1126 Radiographic Progression Free Survival (rPFS) Arm 1: lutetium (177Lu) vipivotide tetraxetan Participant will receive 7.4 GBq (+/- 10%) lutetium (177Lu) vipivotide tetraxetan, once every 6 weeks (+/- 1 week) for a planned 6 cycles, in addition to the Standard of Care (SOC); ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Arm 2: For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Patients with metastatic Hormone Sensitive Prostate Cancer (mHSPC) Primary Analysis: 2024 Publication 94 Investor Relations | Q1 2022 Results TBD TBD 1 NOVARTIS | Reimagining Medicine#95Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health KisqaliⓇ - CDK4/6 inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03701334 NATALEE (CLEE011012301C) Adjuvant treatment of hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC) Phase 3 5101 Invasive Disease-Free Survival for using STEEP criteria (Standardized Definitions for Efficacy End Points in adjuvant breast cancer trials) Ribociclib endocrine therapy Endocrine therapy Pre and postmenopausal women and men with HR-positive, HER2-negative EBC, after adequate surgical resection, who are eligible for adjuvant endocrine therapy 2023 Target Patients Read-out Milestone(s) Publication TBD 95 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#96Company overview CRM Financial performance Immunology PiqrayⓇ - Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health PI3K-alpha inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04208178 EPIK-B2 (CBYL719G12301) HER-2 positive breast cancer Phase 3 548 Progression-free survival (PFS) Alpelisib + trastuzumab + pertuzumab Trastuzumab + pertuzumab Target Patients Patients with HER2-positive advanced breast cancer with a PIK3CA mutation Read-out Milestone(s) 2025 Publication TBD NCT04251533 EPIK-B3 (CBYL719H12301) Triple negative breast cancer Phase 3 566 Progression-free Survival (PFS) for patients with PIK3CA mutant status Alpelisib 300 mg + nab-paclitaxel 100 mg/m² Placebo nab-paclitaxel 100 mg/m² Patients with advanced triple negative breast cancer with either Phosphoinositide-3- kinase Catalytic Subunit Alpha (PIK3CA) mutation or Phosphatase and Tensin Homolog Protein (PTEN) loss without PIK3CA mutation 2023 TBD 96 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#97Company overview CRM Financial performance Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health PiqrayⓇ - PI3K-alpha inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT04729387 EPIK-O (CBYL719K12301) Ovarian Cancer Phase 3 358 Progression Free Survival (PFS) based on Blinded Independent Review Committee (BIRC) assessment using RECIST 1.1 criteria Arm 1 Experimental: Alpelisib+olaparib: Alpelisib 200 mg orally once daily and olaparib 200 mg orally twice daily on a continuous dosing schedule Arm 2 Active Comparator: Paclitaxel or PLD. Investigator's choice of one of 2 single agent cytotoxic chemotherapies: Paclitaxel 80 mg/m2 intravenously weekly or Pegylated liposomal Doxorubicin (PLD) 40-50 mg/m2 (physician discretion) intravenously every 28 days. Patients with platinum resistant or refractory high-grade serous ovarian cancer, with no germline BRCA mutation detected Read-out Milestone(s) 2023 Publication TBD 97 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#98Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health TabrectaⓇ - MET inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT04427072 (CINC280A2301) Non-small cell lung cancer Phase 3 90 Progression free survival (PFS) per blinded independent review committee (BIRC) using RECIST v1.1 Arm 1: 400mg of capmatinib tablets administered orally twice daily Arm 2: Docetaxel 75 mg/m2 by intravenous infusion every 21 days Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (MET?ex14). Primary 2022 Final: 2024 TBD NCT04816214 GEOMETRY-E (CINC280L12301) Non-small cell lung cancer Phase 3 245 Run-in part: Incidence of dose limiting toxicities (DLTs) Randomized part: Progression free survival (PFS) Arm 1: Experimental: Combination of capmatinib + osimertinib (run-in part). Arm 2: Experimental: Combination of capmatinib + osimertinib (randomized part) Arm 3: Active Comparator: platinum + pemetrexed based doublet chemotherapy Adult subjects with Non-small Cell Lung cancers as second line therapy Primary: 2025 Final: 2027 TBD 98 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#99Company overview Financial review Financial performance CRM Immunology Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Tafinlar + MekinistⓇ - BRAF inhibitor and MEK inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04940052 (CDRB436J12301) Thyroid cancer Phase 3 150 Progression Free Survival Arm 1: Experimental: Dabrafenib plus trametinib Participants will be treated with dabrafenib twice daily and trametinib once daily Arm 2: Placebo Comparator: Placebo dabrafenib plus placebo trametinib Participants will receive placebo dabrafenib twice daily and placebo trametinib once daily Previously treated patients with locally advanced or metastatic, radio-active lodine refractory BRAFV600E mutation-positive differentiated thyroid cancer Target Patients Read-out Milestone(s) 2024 Publication TBD 99 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#100Company overview Financial review Financial performance CRM Immunology Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Tafinlar + MekinistⓇ - BRAF inhibitor and MEK inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT02684058 (CDRB436G2201) BRAFV600 mutant gliomas Phase 2 142 Objective response rate Dabrafenib + trametinib (dose based on age and weight) Children and adolescent patients with BRAF V600 mutation positive relapsed or refractory high grade glioma (HGG) or BRAF V600 mutation positive low grade glioma (LGG) Q4 2021 (actual) TBD 100 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#101Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Hematology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health 101 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#102Company overview CRM Financial performance Immunology AdakveoⓇ Financial review Neuroscience - 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health P-selectin inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03814746 STAND (CSEG101A2301) Prevention of Vaso-Occlusive Crises (VOC) in patients with Sickle Cell Disease (SCD) Phase 3 240 Rate of VOC events leading to healthcare visit Crizanlizumab 5.0 mg/kg Crizanlizumab 7.5 mg/kg Placebo Adolescent and adult SCD patients (12 years and older) Target Patients Read-out Milestone(s) 2022 Publication TBD 102 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#103Company overview CRM Financial performance Immunology AdakveoⓇ Financial review Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health - P-selectin inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) NCT03474965 SOLACE-Kids (CSEG101B2201) Prevention of VOC in pediatric patients with SCD Phase 2 100 PK/PD and safety of SEG101 at 5 mg/kg SEG101 (crizanlizumab) at a dose of 5 mg/kg by IV infusion ± Hydroxyurea/Hydroxycarbamide Pediatric SCD patients with VOC H2-2021 (pediatric patients >=12 year old) 2024 (pediatric patients <12 year old) Publication TBD 103 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#104Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health JakaviⓇ - JAK 1/2 inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03491215 REACH4 (CINC424F12201) Acute graft versus host disease Phase 2 45 Measurement of PK parameters Overall Response Rate (ORR) Ruxolitinib NCT03774082 REACH5 (CINC424G12201) Chronic graft versus host disease Phase 2 45 Overall Response Rate (ORR) Ruxolitinib 5mg tablets / pediatric formulation Pediatric patients with grade II-IV acute graft vs. host disease after allogeneic hematopoietic stem cell transplantation Pediatric subjects with moderate and severe chronic Graft vs. Host disease after allogeneic stem cell transplantation Target Patients Read-out Milestone(s) 2023 Publication TBD 104 Investor Relations | Q1 2022 Results 2023 TBD 1 NOVARTIS | Reimagining Medicine#105Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health JakaviⓇ - JAK 1/2 inhibitor Study Indication Phase Patients NCT04097821 ADORE (CINC424H12201) Myelofibrosis Phase 1/2 130 Primary Outcome Measures Arms Intervention Incidence of dose limiting toxicities within the first 2 cycles Response rate at the end of cycle 6 Ruxolitinib Ruxolitinib+Siremadlin Ruxolitinib+Crizanlizumab Ruxolitinib+MBG453 Ruxolitinib+LTT462 Ruxolitinib+NIS793 Patients with Myelofibrosis (MF) Target Patients Read-out Milestone(s) Publication 2024 TBD 105 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#106Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology KymriahⓇ - CD19 CAR-T Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03570892 BELINDA (CCTL019H2301) 2nd line Diffuse large B-cell lymphoma (DLBCL) Phase 3 318 Event-free Survival (EFS) Tisagenlecleucel versus standard of care Adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline- containing frontline immunochemotherapy Target Patients Read-out Milestone(s) 9 Jul 2021 (actual) Publication Bishop et al at SITC 2019 Abstract submission TBD NCT03876769 CASSIOPEIA (CCTL019G2201J) 1st line high risk acute lymphoblastic leukemia (ALL) Phase 2 160 Disease Free Survival (DFS) Single-arm study of tisagenlecleucel Pediatric and young adult patients with 1st line high risk ALL 2025 TBD 106 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#107Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors References Abbreviations Hematology Biosimilars Global Health PromactaⓇ - Thrombopoetin receptor agonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT03025698 (CETB115E2201) Refractory or relapsed severe aplastic anemia Phase 2 51 PK of eltrombopag at steady state in pediatric patients with SAA Eltrombopag 12.5, 25, 50, 75 mg FCT & 25 mg pFOS Arm A: relapsed/refractory SAA or recurrent AA following IST for SAA: hATG/cyclosporine + eltrombopag or cyclosporine + eltrombopag Arm B: previously untreated SAA: hATG/cyclosporine + eltrombopag Pediatric patients from age 1 <18 years with relapsed/refractory SAA or recurrent AA after IST or previously untreated SAA Primary CSR: 2022 Final CSR: 2025 TBD NCT03988608 (CETB115E2202) Refractory or relapsed severe aplastic anemia Phase 2 20 Hematologic response rate rate up to 26 weeks of treatment Eltrombopag 25 mg film-coated tablets Chinese patients with refractory or relapsed severe aplastic anemia Primary CSR: 2022 Final CSR: 2025 TBD 107 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#108Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors RydaptⓇ - Multi-targeted kinase inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03591510 (CPKC412A2218) Acute myeloid leukemia, pediatrics Phase 2 20 Occurrence of dose limiting toxicities Safety and Tolerability Chemotherapy followed by Midostaurin Newly diagnosed pediatric patients with FLT3 mutated acute myeloid leukemia (AML) Target Patients Read-out Milestone(s) 2026 Publication TBD References Abbreviations Hematology Biosimilars Global Health 108 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#109Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors ScemblixⓇ- BCR-ABL inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04971226 ASC4FIRST (CABL001J12301) Chronic myeloid leukemia, 1st line Phase 3 402 Major Molecular Response (MMR) at week 48 Arm 1: asciminib 80 mg QD Arm 2: Investigator selected TKI including one of the below treatments: -Imatinib 400 mg QD - Nilotinib 300 mg BID - Dasatinib 100 mg QD - Bosutinib 400 mg QD Patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase Target Patients Read-out Milestone(s) 2024 Publication TBD 109 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine#110Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health iptacopan - CFB inhibitor - HEM Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT04558918 APPLY-PNH (CLNP023C12302) Paroxysmal nocturnal haemoglobinuria Phase 3 91 Percentage of participants achieving a sustained increase in hemoglobin levels of >= 2 g/dL in the absence of red blood cell transfusions Percentage of participants achieving sustained hemoglobin levels >= 12 g/dL in the absence of red blood cell transfusions Arm 1: Drug: LNP023, taken orally b.i.d. dosage supplied: 200 mg dosage form: hard gelatin capsule Route of Administration: Oral Arm 2: Drug: Eculizumab, administered as intravenous infusion every 2 weeks as per the stable regimen, the maintenance dose is a fixed dose. Dosage supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion Drug: Ravulizumab, administered as intravenous infusion every 8 weeks, the maintenance dose is based on body weight. Dosage Supplied: 300 mg/30mL Dosage f Adult patients with PNH and residual anemia, despite treatment with an intravenous Anti-C5 antibody Primary 2022 Risitano AM, et al. Abstract accepted at the European Hematology Association (EHA 2021) congress (study design abstract; accepted for publication only) NCT04820530 APPOINT-PNH (CLNP023C12301) Paroxysmal nocturnal haemoglobinuria Phase 3 40 Proportion of participants achieving a sustained increase from baseline in hemoglobin levels of ? 2 g/dL assessed, in the absence of red blood cell transfusions Iptacopan (LNP023), taken orally b.i.d. (dosage supplied: 200mg) PNH patients who are naive to complement inhibitor therapy, including anti-C5 antibody 2023 Peffault de Latour R, et al. Abstract accepted at the European Hematology Association (EHA 2021) congress (study design abstract; accepted for publication only) 110 Investor Relations | Q1 2022 Results U NOVARTIS | Reimagining Medicine#111Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology iptacopan - CFB inhibitor Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04889430 APPELHUS (CLNP023F12301) Atypical haemolytic uraemic syndrome Phase 3 50 Percentage of participants with complete TMA response without the use of PE/PI and anti-C5 antibody Single arm open-label with 50 adult patients receiving 200mg oral twice daily doses of iptacopan Adult patients with aHUS who are treatment naive to complement inhibitor therapy (including anti-C5 antibody) Target Patients Read-out Milestone(s) 2024 Publication TBD References Abbreviations Hematology Biosimilars Global Health 111 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#112Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health sabatolimab - TIM3 antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03946670 STIMULUS MDS-1 (CMBG453B12201) Myelodysplastic syndrome Phase 2 120 Complete Remission (CR) rate and Progression Free Survival (PFS) Experimental: Sabatolimab (MBG453) + hypomethylating agents Placebo comparator: Placebo + hypomethylating agents Adult subjects with intermediate, high or very high risk Myelodysplastic Syndrome (MDS) as per IPSS-R criteria Target Patients Read-out Milestone(s) 2022-2023 Publication TBD NCT04150029 STIMULUS-AML1 (CMBG453C12201) Unfit acute myeloid leukaemia Phase 2 86 Incidence of dose limiting toxicities (Safety run-in patients only) Percentage of subjects achieving complete remission (CR) Single arm safety and efficacy study of sabatolimab in combination with azacitidine and venetoclax Newly diagnosed adult AML patients who are not suitable for treatment with intensive chemotherapy 2023 TBD 112 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#113Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors sabatolimab - TIM3 antagonist Study Indication Phase Patients Primary Outcome Measures NCT04266301 STIMULUS-MDS2 (CMBG453B12301) Myelodysplastic syndrome Phase 3 500 Overall survival Arms Intervention Sabatolimab 800 mg + azacitidine 75 mg/m2 Sabatolimab 800 mg + azacitidine 75 mg/m2 + placebo Patients with intermediate, high or very high risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) Target Patients Read-out Milestone(s) 2023 Publication TBD References Abbreviations Hematology Biosimilars Global Health 113 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#114Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Biosimilars Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health 114 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#115Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Ophthalmology Respiratory & Allergy Oncology: Solid Tumors aflibercept - VEGF inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04864834 Mylight (CSOK583A12301) Aflibercept BioS Phase 3 460 Best-corrected visual acuity (BCVA) will be assessed using the ETDRS testing charts at an initial distance of 4 meters. The change from baseline in BCVA in letters is defined as difference between BCVA score between week 8 and baseline Arm 1 Biological: SOK583A1 (40 mg/mL) Arm 2 Biological: Eylea EU (40 mg/mL) Patients with neovascular age-related macular degeneration Target Patients Read-out Milestone(s) 2023 Publication tbd References Abbreviations Hematology Biosimilars Global Health 115 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#116Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Ophthalmology Respiratory & Allergy Oncology: Solid Tumors denosumab - anti RANKL mAb Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03974100 (CGP24112301) Denosumab BioS Phase 3 522 Percent change from baseline (%CfB) in lumbar spine Bone Mineral Density GP2411 60 mg/mL subcutaneous injection every 6 months ProliaⓇ 60 mg/mL subcutaneous injection every 6 months Postmenopausal women with osteoporosis Target Patients Read-out Milestone(s) 2022 Publication Study data publications expected for 2024 and beyond. The overall study design will be published at WCO and ECTS congresses 2020. 116 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine#117Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Global Health Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health 117 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine#118Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors artemether + lumefantrine Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04300309 CALINA (CCOA566B2307) Malaria, uncomplicated (<5kg patients) Phase 3 Artemether Cmax Target Patients Read-out Milestone(s) Experimental: artemether lumefantrine (2.5 mg:30 mg) artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per dose Infants and Neonates <5 kg body weight with acute uncomplicated plasmodium falciparum malaria Primary outcome measure: 2023 Publication TBD References Abbreviations Hematology Biosimilars Global Health 118 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#119Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors Hematology Innovation: Pipeline overview Ophthalmology ganaplacide - Imidazolopiperazines derivative Study Indication Phase Patients Primary Outcome Measures NCT03167242 (CKAF156A2202) Malaria Phase 2 PCR-corrected adequate clinical and parasitological response (ACPR) NCT04546633 KALUMI (CKAF156A2203) Malaria, uncomplicated Phase 2 References Abbreviations Biosimilars Global Health PCR-corrected and uncorrected Adequate Clinical and Parasitological Response (ACPR) KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition Malaria patients 12 to < 18 years old with malaria caused by P. falciparum Arms Intervention KAF156 and LUM-SDF (different combinations) Coartem Target Patients Adults and children with uncomplicated Plasmodium falciparum malaria Read-out Milestone(s) H2-2021 (actual) 2023 Publication CSR final in CREDI 20Dec2021 TBD 119 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine#120Company overview Financial performance Financial review Abbreviations 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials aHUS ALL ALS aBC AD Adj. AIH Advanced breast cancer Atopic Dermatitis Adjuvant Autoimmune hepatitis atypical Hemolytic Uremic Syndrome Acute lymphoblastic leukemia Amyotrophic lateral sclerosis HF-REF HNSCC HS ΙΑ IgAN iMN IPF AMI Acute myocardial infarction JIA AML Acute myeloid leukemia jPSA/ERA aNHL Agressive non-Hodgkin's lymphoma AS H2H Ankylosing spondylitis head-to-head study versus adalimumab LVEF mCRPC BC Breast cancer MDR C3G C3 glomerulopathy MDS CCF CINDU Congestive cardiac failure Chronic inducible urticaria MS NASH CLL CML Chronic lymphocytic leukemia Chronic myeloid leukemia nHCM nr-axSpA Chronic heart failure with reduced ejection fraction Head and neck squamous cell carcinoma Hidradenitis suppurativa Interim analysis IgA nephropathy Membranous nephropathy Idiopathic pulmonary fibrosis Juvenile idiopathic arthritis Juvenile psoriatic arthritis / enthesitis-related arthritis Left ventricular ejection fraction Metastatic castration-resistant prostate cancer Multi-drug resistant Myelodysplastic syndrome Multiple sclerosis Non-alcoholic steatohepatitis Non-obstructive hypertrophic cardiomyopathy Non-radiographic axial spondyloarthritis CRC Colorectal cancer COPD Chronic obstructive pulmonary disease NSCLC PEF Non-small cell lung cancer Preserved ejection fraction COSP Chronic ocular surface pain PedPsO Pediatric psoriasis CRSWNP Severe chronic rhinosinusitis with nasal polyps PNH CSU Chronic spontaneous urticaria PsA CVRR-Lp(a) CVRR-LDLC DME Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a) Secondary prevention of cardiovascular events in patients with elevated levels of LDLC Diabetic macular edema PROS RA rMS DLBCL ESCC FL GCA GVHD HCC HD HFPEF Diffuse large B-cell lymphoma refractory Esophageal squamous-cell carcinoma Follicular lymphoma Giant cell arteritis Graft-versus-host disease Hepatocellular carcinoma Huntington's disease Chronic heart failure with preserved ejection fraction RVO Retinal vein occlusion SAA SLE SpA SPMS TNBC T1DM Type 1 Diabetes mellitus SMA Type 1 SMA Type 2/3 Paroxysmal nocturnal haemoglobinuria Psoriatic arthritis PIK3CA related overgrowth spectrum Rheumatoid arthritis Relapsing multiple sclerosis Severe aplastic anemia Systemic lupus erythematosus Spinal muscular atrophy (IV formulation) Spinal muscular atrophy (IT formulation) Spondyloarthritis Secondary progressive multiple sclerosis Triple negative breast cancer 120 Investor Relations | Q1 2022 Results References Abbreviations U NOVARTIS | Reimagining Medicine#121Company overview Financial review 2022 priorities Appendix References References ENTRESTO 1 IQVIA National Prescription Audit as of 25/03/2022. 2 Approved indications differ by geography. Examples include "indicated to reduce the risk of cardiovascular death and hospitalization for HF in adult patients with CHF. Benefits are most clearly evident in patients with LVEF below normal." (US) HFrEF (EU) HFrEF and HTN (China and JP). 3 Zhang et al., ESC Heart Failure 2020; 7: 3841 4 Proudfoot et al., Int J Cardiol. 2021; 331:164 5 Including, but not limited to, the recent 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (Heidenreich et al., J Am Coll Cardiol. 2022) KESIMPTA 1 Hauser S, et. al. Long-term safety of ofatumumab in patients with relapsing multiple sclerosis. Presented at American Academy of Neurology 2022 (S14.004). 2 Hauser S. et al. Long-term efficacy of ofatumumab in patients with relapsing multiple sclerosis. Presented at American Academy of Neurology 2022 (P5.004) 3 Ziemssen T, et al. KYRIOS clinical trial: Tracking the immune response to SARS-CoV-2 mRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. Presented at American Academy of Neurology 2022, Levit E, et al. Mult Scler Relat Disord. 2022 Mar 3;60:103719 4 Based on SHP APLD representing 9K patients through Jan 2022 * *IQVIA National Prescription Audit (NPA) data projected and scaled to IQVIA National Sales Perspectives (NSP) volume (national derivative of IQVIA Drug Distribution Data (DDD)) 121 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine